Delaware | 05-0494040 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
One CVS Drive, Woonsocket, Rhode Island | 02895 | |
(Address of principal executive offices) | (Zip Code) |
Common Stock, par value $0.01 per share | New York Stock Exchange | |
Title of each class | Name of each exchange on which registered |
Large accelerated filer x | Accelerated filer o | |
Non-accelerated filer o (Do not check if a smaller reporting company) | Smaller reporting company o |
Page | |||
Part I | |||
Part II | |||
Part III | |||
Part IV | |||
Percentage of Net Revenues(1) | ||||||||
2014 | 2013 | 2012 | ||||||
Prescription drugs | 70.7 | % | 69.5 | % | 68.8 | % | ||
Over-the-counter and personal care | 11.0 | 11.0 | 10.9 | |||||
Beauty/cosmetics | 4.7 | 4.9 | 5.0 | |||||
General merchandise and other | 13.6 | 14.6 | 15.3 | |||||
100.0 | % | 100.0 | % | 100.0 | % |
(1) | Percentages are estimates based on store point-of-sale data. |
• | federal and state laws and regulations concerning the submission of claims for reimbursement by Medicare, Medicaid and other government programs; |
• | federal and state laws and regulations governing the purchase, distribution, tracking, management, compounding, dispensing and reimbursement of prescription drugs and related services, whether at retail or mail, and applicable registration or licensing requirements; |
• | the effect of the expiration of patents covering brand name drugs and the introduction of generic products; |
• | the frequency and rate of approvals by the FDA of new brand name and generic drugs, or of over-the-counter status for brand name drugs; |
• | rules and regulations issued pursuant to HIPAA and the HITECH Act; and other federal and state laws affecting the collection, use, disclosure and transmission of health or other personal information, such as federal laws on information privacy precipitated by concerns about information collection through the Internet, state security breach laws and state laws limiting the use and disclosure of prescriber information; |
• | consumer protection laws affecting our health care services, our loyalty programs, the products we sell, the informational calls we make and/or the marketing of our goods and services; |
• | federal, state and local environmental, health and safety laws and regulations applicable to our business, including the management of hazardous substances, storage and transportation of hazardous materials, and various recordkeeping disclosure and procedure requirements promulgated by the Occupational Safety and Health Administration that may apply to our operations; |
• | health care reform, managed care reform and plan design legislation; |
• | FDA regulation affecting the retail or PBM industry; |
• | government regulation of the development, administration, review and updating of formularies and drug lists including requirements and/or limitations around formulary tiering and patient cost sharing; |
• | federal and state laws and regulations establishing or changing prompt payment requirements for payments to retail pharmacies; |
• | impact of network access legislation or regulations, including “any willing provider” laws, on our ability to manage pharmacy networks; |
• | administration of Medicare Part D, including legislative changes and/or CMS rulemaking and interpretation; |
• | insurance licensing and other insurance regulatory requirements applicable to offering Medicare Part D programs and services or other health care services; |
• | government regulation allowing the importation of prescription drugs from Canada and elsewhere into the United States; and |
• | direct regulation of pharmacies or PBMs by regulatory and quasi-regulatory bodies. |
Retail Stores | Onsite Pharmacy Stores | Specialty Pharmacy Stores | Specialty Mail Order Pharmacies | Mail Order Dispensing Pharmacies | Infusion & Enteral Services Locations | Total | |||||||||||||||
United States: | |||||||||||||||||||||
Alabama | 158 | — | 1 | — | — | 1 | 160 | ||||||||||||||
Arkansas | 5 | — | — | — | — | 1 | 6 | ||||||||||||||
Arizona | 144 | — | 1 | — | — | 2 | 147 | ||||||||||||||
California | 862 | — | 4 | 1 | — | 10 | 877 | ||||||||||||||
Colorado | — | — | 1 | — | — | 2 | 3 | ||||||||||||||
Connecticut | 151 | 1 | — | — | — | 1 | 153 | ||||||||||||||
Delaware | 15 | — | — | — | — | — | 15 | ||||||||||||||
District of Columbia | 59 | — | 1 | — | — | — | 60 | ||||||||||||||
Florida | 753 | — | 3 | 1 | — | 9 | 766 | ||||||||||||||
Georgia | 315 | 2 | 1 | — | — | 1 | 319 | ||||||||||||||
Hawaii | 54 | — | 1 | — | 1 | — | 56 | ||||||||||||||
Idaho | — | — | — | — | — | 1 | 1 | ||||||||||||||
Iowa | 18 | 1 | — | — | — | 1 | 20 | ||||||||||||||
Illinois | 275 | 1 | — | 1 | 1 | 2 | 280 | ||||||||||||||
Indiana | 298 | — | — | — | — | 4 | 302 | ||||||||||||||
Kansas | 39 | — | — | 1 | — | 2 | 42 | ||||||||||||||
Kentucky | 66 | — | — | — | — | — | 66 | ||||||||||||||
Louisiana | 113 | — | — | — | — | 1 | 114 | ||||||||||||||
Maine | 22 | — | — | — | — | 1 | 23 | ||||||||||||||
Maryland | 174 | 1 | — | — | — | 1 | 176 | ||||||||||||||
Massachusetts | 358 | — | 2 | 1 | — | 2 | 363 | ||||||||||||||
Michigan | 246 | 1 | — | 1 | — | 2 | 250 | ||||||||||||||
Minnesota | 59 | 1 | — | — | — | 3 | 63 | ||||||||||||||
Mississippi | 50 | — | — | — | — | 1 | 51 | ||||||||||||||
Missouri | 87 | 1 | 1 | — | — | 2 | 91 | ||||||||||||||
Montana | 14 | — | — | — | — | — | 14 | ||||||||||||||
Nebraska | 18 | — | — | — | — | 1 | 19 | ||||||||||||||
Nevada | 85 | — | — | — | — | 2 | 87 | ||||||||||||||
New Hampshire | 41 | — | — | — | — | — | 41 | ||||||||||||||
New Jersey | 279 | 2 | — | 1 | — | 1 | 283 | ||||||||||||||
New Mexico | 17 | — | — | — | — | 1 | 18 | ||||||||||||||
New York | 480 | — | 1 | — | — | 7 | 488 | ||||||||||||||
North Carolina | 312 | — | 1 | 1 | — | 3 | 317 | ||||||||||||||
North Dakota | 6 | — | — | — | — | — | 6 | ||||||||||||||
Ohio | 319 | 2 | — | — | — | 4 | 325 | ||||||||||||||
Oklahoma | 61 | — | — | — | — | 1 | 62 | ||||||||||||||
Oregon | — | — | 1 | — | — | 1 | 2 | ||||||||||||||
Pennsylvania | 406 | 1 | 1 | 1 | 1 | 3 | 413 | ||||||||||||||
Puerto Rico | 20 | — | — | 1 | — | — | 21 | ||||||||||||||
Rhode Island | 63 | — | 1 | — | — | 1 | 65 | ||||||||||||||
South Carolina | 192 | — | 1 | — | — | 2 | 195 | ||||||||||||||
Tennessee | 134 | 1 | — | 1 | — | 3 | 139 | ||||||||||||||
Texas | 617 | 1 | 3 | — | 1 | 5 | 627 | ||||||||||||||
Utah | 5 | — | — | — | — | 1 | 6 | ||||||||||||||
Vermont | 6 | — | — | — | — | — | 6 | ||||||||||||||
Virginia | 279 | — | 1 | — | — | 2 | 282 | ||||||||||||||
Washington | 3 | — | 1 | — | — | 3 | 7 | ||||||||||||||
West Virginia | 50 | — | — | — | — | — | 50 | ||||||||||||||
Wisconsin | 47 | 1 | — | — | — | 1 | 49 | ||||||||||||||
Total United States | 7,775 | 17 | 27 | 11 | 4 | 92 | 7,926 | ||||||||||||||
Brazil | 47 | — | — | — | — | — | 47 | ||||||||||||||
Total | 7,822 | 17 | 27 | 11 | 4 | 92 | 7,973 |
First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Year | ||||||||||||||||||
2014 | High | $ | 76.36 | $ | 79.43 | $ | 82.57 | $ | 98.62 | $ | 98.62 | |||||||||||
Low | $ | 64.95 | $ | 72.37 | $ | 74.69 | $ | 77.40 | $ | 64.95 | ||||||||||||
Cash dividends per common share | $ | 0.275 | $ | 0.275 | $ | 0.275 | $ | 0.275 | $ | 1.10 | ||||||||||||
2013 | High | $ | 56.07 | $ | 60.70 | $ | 62.36 | $ | 71.99 | $ | 71.99 | |||||||||||
Low | $ | 49.00 | $ | 53.94 | $ | 56.68 | $ | 56.32 | $ | 49.00 | ||||||||||||
Cash dividends per common share | $ | 0.225 | $ | 0.225 | $ | 0.225 | $ | 0.225 | $ | 0.90 |
Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs | ||||||||||
October 1, 2014 through October 31, 2014 | 7,325,187 | $ | 81.70 | 7,325,187 | $ | 3,293,630,647 | ||||||||
November 1, 2014 through November 30, 2014 | 6,650,000 | $ | 88.37 | 6,650,000 | $ | 2,705,958,545 | ||||||||
December 1, 2014 through December 31, 2014 | 153,295 | $ | 90.42 | 153,295 | $ | 12,692,098,316 | ||||||||
14,128,482 | 14,128,482 |
In millions, except per share amounts | 2014 | 2013 | 2012 | 2011 | 2010 | ||||||||||||||
Statement of operations data: | |||||||||||||||||||
Net revenues | $ | 139,367 | $ | 126,761 | $ | 123,120 | $ | 107,080 | $ | 95,766 | |||||||||
Gross profit | 25,367 | 23,783 | 22,488 | 20,562 | 20,215 | ||||||||||||||
Operating expenses | 16,568 | 15,746 | 15,278 | 14,231 | 14,082 | ||||||||||||||
Operating profit | 8,799 | 8,037 | 7,210 | 6,331 | 6,133 | ||||||||||||||
Interest expense, net | 600 | 509 | 557 | 584 | 536 | ||||||||||||||
Loss on early extinguishment of debt | 521 | — | 348 | — | — | ||||||||||||||
Income tax provision(1) | 3,033 | 2,928 | 2,436 | 2,258 | 2,178 | ||||||||||||||
Income from continuing operations | 4,645 | 4,600 | 3,869 | 3,489 | 3,419 | ||||||||||||||
Income (loss) from discontinued operations, net | |||||||||||||||||||
of tax | (1 | ) | (8 | ) | (7 | ) | (31 | ) | 2 | ||||||||||
Net income | 4,644 | 4,592 | 3,862 | 3,458 | 3,421 | ||||||||||||||
Net loss attributable to noncontrolling interest | — | — | 2 | 4 | 3 | ||||||||||||||
Net income attributable to CVS Health | $ | 4,644 | $ | 4,592 | $ | 3,864 | $ | 3,462 | $ | 3,424 | |||||||||
Per common share data: | |||||||||||||||||||
Basic earnings per common share: | |||||||||||||||||||
Income from continuing operations attributable to CVS Health | $ | 3.98 | $ | 3.78 | $ | 3.05 | $ | 2.61 | $ | 2.50 | |||||||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | — | ||||||
Net income attributable to CVS Health | $ | 3.98 | $ | 3.77 | $ | 3.04 | $ | 2.59 | $ | 2.50 | |||||||||
Diluted earnings per common share: | |||||||||||||||||||
Income from continuing operations attributable to CVS Health | $ | 3.96 | $ | 3.75 | $ | 3.02 | $ | 2.59 | $ | 2.49 | |||||||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | — | ||||||
Net income attributable to CVS Health | $ | 3.96 | $ | 3.74 | $ | 3.02 | $ | 2.57 | $ | 2.49 | |||||||||
Cash dividends per common share | $ | 1.10 | $ | 0.90 | $ | 0.65 | $ | 0.50 | $ | 0.35 | |||||||||
Balance sheet and other data: | |||||||||||||||||||
Total assets | $ | 74,252 | $ | 71,526 | $ | 66,221 | $ | 64,852 | $ | 62,457 | |||||||||
Long-term debt | $ | 11,695 | $ | 12,841 | $ | 9,133 | $ | 9,208 | $ | 8,652 | |||||||||
Total shareholders’ equity | $ | 37,963 | $ | 37,938 | $ | 37,653 | $ | 38,014 | $ | 37,662 | |||||||||
Number of stores (at end of year) | 7,866 | 7,702 | 7,508 | 7,388 | 7,248 |
(1) | Income tax provision for the year ended December 31, 2010 includes the effect of the recognition of $47 million of previously unrecognized tax benefits, including interest, relating to the expiration of various statutes of limitation and settlements with tax authorities. |
Number of securities to be issued upon exercise of outstanding options, warrants and rights(1) | Weighted average exercise price of outstanding options, warrants and rights | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in first column) (1) | |||||||
Equity compensation plans approved by stockholders | 28,165 | $ | 47.87 | 30,237 | |||||
Equity compensation plans not approved by stockholders | — | — | — | ||||||
Total | 28,165 | $ | 47.87 | 30,237 |
(1) | Shares in thousands. |
Consolidated Statements of Income for the Years Ended December 31, 2014, 2013 and 2012 | 27 | ||
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2014, 2013 and 2012 | 28 | ||
Consolidated Balance Sheets as of December 31, 2014 and 2013 | 29 | ||
Consolidated Statements of Cash Flows for the Years Ended December 31, 2014, 2013 and 2012 | 30 | ||
Consolidated Statements of Shareholders’ Equity for the Years Ended December 31, 2014, 2013 and 2012 | 31 | ||
Notes to Consolidated Financial Statements | 32 | ||
Report of Independent Registered Public Accounting Firm | 59 |
Exhibit | Description | |
2.1* | Agreement and Plan of Merger dated as of November 1, 2006 among, the Registrant, Caremark Rx, Inc. and Twain MergerSub Corp. (incorporated by reference to Exhibit 2.1 to the Registrant’s Registration Statement No. 333-139470 on Form S-4 filed December 19, 2006). | |
2.2* | Amendment No. 1 dated as of January 16, 2007 to the Agreement and Plan of Merger dated as of November 1, 2006 among the Registrant, Caremark Rx, Inc. and Twain Merger Sub Corp. (incorporated by reference to Exhibit 2.2 to the Registrant’s Registration Statement No. 333-139470 on Form S-4/A filed January 16, 2007). | |
2.3* | Waiver Agreement dated as of January 16, 2007 between the Registrant and Caremark Rx, Inc. with respect to the Agreement and Plan Merger dated as of November 1, 2006 by and between Registrant and Caremark Rx, Inc (incorporated by reference to Exhibit 2.3 to the Registrant’s Registration Statement No. 333-139470 on Form S-4/A filed January 16, 2007). | |
2.4* | Amendment to Waiver Agreement, dated as of February 12, 2007, between Registrant and Caremark Rx, Inc. (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K dated February 13, 2007; Commission File No. 001-01011). | |
2.5* | Amendment to Waiver Agreement, dated as of March 8, 2007, between Registrant and Caremark Rx, Inc. (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K dated March 8, 2007; Commission File No. 001-01011). | |
2.6* | Agreement and Plan of Merger dated as of August 12, 2008 among, the Registrant, Longs Drug Stores Corporation and Blue MergerSub Corp. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K dated August 13, 2008; Commission File No. 001-01011). | |
3.1* | Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1996; Commission File No. 001-01011). |
3.1A* | Certificate of Amendment to the Amended and Restated Certificate of Incorporation, effective May 13, 1998 (incorporated by reference to Exhibit 4.1A to Registrant’s Registration Statement No. 333-52055 on Form S-3/A dated May 18, 1998). | |
3.1B* | Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K dated March 22, 2007; Commission File No. 001-01011). | |
3.1C* | Certificate of Merger dated May 9, 2007 (incorporated by reference to Exhibit 3.1C to Registrant’s Quarterly Report on Form 10-Q dated November 1, 2007; Commission File No. 001-01011). | |
3.1D* | Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to Registrant’s Current Report on Form 8-K dated May 13, 2010; Commission File No. 001-01011). | |
3.1E* | Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report On Form 8-K dated May 10, 2012; Commission File No. 001-01011). | |
3.1F* | Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K dated September 3, 2014 (Commission File No. 001-01011)). | |
3.2* | By-laws of the Registrant, as amended and restated (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K dated September 3, 2014; Commission File No. 001-01011). | |
4 | Pursuant to Regulation S-K, Item 601(b)(4)(iii)(A), no instrument which defines the rights of holders of long-term debt of the Registrant and its subsidiaries is filed with this report. The Registrant hereby agrees to furnish a copy of any such instrument to the Securities and Exchange Commission upon request. | |
4.1* | Specimen common stock certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement of the Registrant on Form 8-B dated November 4, 1996; Commission File No. 001-01011). | |
10.1* | Stock Purchase Agreement dated as of October 14, 1995 between The TJX Companies, Inc. and Melville Corporation, as amended November 17, 1995 (incorporated by reference to Exhibits 2.1 and 2.2 to Melville’s Current Report on Form 8-K dated December 4, 1995; Commission File No. 001-01011). | |
10.2* | Stock Purchase Agreement dated as of March 25, 1996 between Melville Corporation and Consolidated Stores Corporation, as amended May 3, 1996 (incorporated by reference to Exhibits 2.1 and 2.2 to Melville’s Current Report on Form 8-K dated May 5, 1996; Commission File No. 001-01011). | |
10.3* | Distribution Agreement dated as of September 24, 1996 among Melville Corporation, Footstar, Inc. and Footstar Center, Inc. (incorporated by reference to Exhibit 99.1 to Melville’s Current Report on Form 8-K dated October 28, 1996; Commission File No. 001-01011). | |
10.4* | Tax Disaffiliation Agreement dated as of September 24, 1996 among Melville Corporation, Footstar, Inc. and certain subsidiaries named therein (incorporated by reference to Exhibit 99.2 to Melville’s Current Report on Form 8-K dated October 28, 1996; Commission File No. 001-01011). | |
10.5* | Stockholder Agreement dated as of December 2, 1996 between the Registrant, Nashua Hollis CVS, Inc. and Linens ‘n Things, Inc. (incorporated by reference to Exhibit 10(i)(6) to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997; Commission File No. 001-01011). | |
10.6* | Tax Disaffiliation Agreement dated as of December 2, 1996 between the Registrant and Linens ‘n Things, Inc. and certain of their respective affiliates (incorporated by reference to Exhibit 10(i)(7) to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 1997; Commission File No. 001-01011). | |
10.7* | Four Year Credit Agreement dated as of May 12, 2011 by and among the Registrant, the lenders party thereto, Barclays Capital and JP Morgan Chase Bank, N.A., as Co-Syndication Agents, Bank of America, N.A. and Wells Fargo Bank, N.A., as Co-Documentation Agents, and the Bank of New York Mellon, as Administrative Agent (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011; Commission File No. 001-01011). | |
10.8* | Amendment No. 1, dated as of November 22, 2011, to the Credit Agreement dated as of May 12, 2011 by and among the Registrant, the Lenders party thereto, the Co-Syndication Agents and Co-Documentation Agents named therein, and The Bank of New York Mellon, as Administrative Agent (incorporated by reference to Exhibit 10.45 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011; Commission File No. 001-01011). |
10.9* | Five Year Credit Agreement dated as of February 17, 2012, by and among the Registrant, the lenders party thereto, Barclays Capital and JPMorgan Chase Bank, N.A., as Co-Syndication Agents, Bank of America, N.A. and Wells Fargo Bank, N.A., as Co-Documentation Agents, and The Bank of New York Mellon, as Administrative Agent (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2012 (Commission File No. 001-01011). | |
10.10* | Credit Agreement dated as of May 23, 2013, by and among the Registrant, the lenders party thereto, Barclays Bank PLC and JPMorgan Chase Bank, N.A., as Co-Syndication Agents, Bank of America, N.A. and Wells Fargo Bank, N.A., as Co-Documentation Agents, and The Bank of New York Mellon, as Administrative Agent. (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013 (Commission File No. 001-01011). | |
10.11* | Amendment No. 2, dated as of May 23, 2013, to the Credit Agreement dated as of May 12, 2011, by and among the Registrant, the lenders party thereto, Barclays Capital and JPMorgan Chase Bank, N.A., as Co-Syndication Agents, Bank of America, N.A. and Wells Fargo Bank, N.A., as Co-Documentation Agents, and The Bank of America, N.A. and Wells Fargo Bank, N.A., as Co-Documentation Agents, and The Bank of New York Mellon, as Administrative Agent, as previously amended by Amendment No. 1, dated as of November 22, 2011 (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013 (Commission File No. 001-01011). | |
10.12* | Second Amended and Restated Credit Agreement, dated as of July 24, 2014, by and among the Registrant, the lenders party thereto, Barclays Bank PLC and JPMorgan Chase Bank, N.A., as Co-Syndication Agents, Bank of America, N.A. and Wells Fargo Bank, N.A., as Co-Documentation Agents, and The Bank of New York Mellon, as Administrative Agent (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 (Commission File No. 001-01011). | |
10.13* | Supplemental Retirement Plan for Select Senior Management of CVS Health Corporation I as amended and restated in December 2008 (incorporated by reference to Exhibit 10.6 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009; Commission File No. 001-01011). | |
10.14* | CVS Health Corporation 1996 Directors Stock Plan, as amended and restated November 5, 2002 (incorporated by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 28, 2002; Commission File No. 001-01011). | |
10.15* | 1997 Incentive Compensation Plan as amended through December 2008 (incorporated by reference to Exhibit 10.8 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009; Commission File No. 001-01011). | |
10.16* | Caremark Rx, Inc. 2004 Incentive Stock Plan (incorporated by reference to Exhibit 99.2 of the Registrant’s Registration Statement No. 333-141481 on Form S-8 filed March 22, 2007; Commission File No. 011-01011). | |
10.17* | CVS Health Deferred Stock Compensation Plan (incorporated by reference to Exhibit 10.4 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009; Commission File No. 011-01011). | |
10.18 | CVS Health Deferred Compensation Plan, as amended and restated as of December 17, 2014. | |
10.19* | 2010 Incentive Compensation Plan, as amended through January 15, 2013 (incorporated by reference to Exhibit 10.30 to the Registrant’s Annual Report on Form10-K for the fiscal year ended December 31, 2012; Commission File No. 001-01011). | |
10.20* | 2007 Employee Stock Purchase Plan (incorporated by reference to Exhibit D of the Registrant’s Definitive Proxy Statement filed April 4, 2007; Commission File No. 001-01011). | |
10.21 | The Registrant’s 2014 Management Incentive Plan. | |
10.22 | The Registrant’s 2014 Executive Incentive Plan. | |
10.23* | The Registrant’s Long-Term Incentive Plan (incorporated by reference to Exhibit 10.21 to the Registrant’s Annual Report on Form10-K for the fiscal year ended December 31, 2013; Commission file No. 001-01011). | |
10.24 | The Registrant’s Partnership Equity Program amended as of December 2014. | |
10.25* | The Registrant’s Severance Plan for Non-Store Employees amended as of April 2013 (incorporated by reference to Exhibit 10.23 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013; Commission File No. 001-01011). | |
10.26 | The Registrant’s Performance-Based Restricted Stock Unit Plan amended as of December 2014. | |
10.27 | Form of Enterprise Non-Competition, Non-Disclosure and Developments Agreement between the Registrant and certain of the Registrant’s executive officers (incorporated by reference to Exhibit 10.25 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013; Commission File No. 001-01011). | |
10.28* | Universal 409A Definition Document dated December 31, 2008 (incorporated by reference to Exhibit 10.7 to the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2009; Commission File No. 001-01011). | |
10.29 | Form of Non-Qualified Stock Option Agreement between the Registrant and selected employees of the Registrant. | |
10.30 | Form of Restricted Stock Unit Agreement - Annual Grant - between the Registrant and selected employees of the Registrant. | |
10.31 | Form of Performance-Based Restricted Stock Unit Agreement between the Registrant and selected employees of the Registrant. | |
10.32 | Form of Partnership Equity Program Participant Purchased RSUs, Company Matching RSUs and Company Matching Options Agreement (Pre-Tax). | |
10.33 | Form of Partnership Equity Program Participant Purchased RSUs, Company Matching RSUs and Company Matching Options Agreement (Post-Tax). | |
10.34* | Amended and Restated Employment Agreement dated as of December 22, 2008 between the Registrant and the Registrant’s President and Chief Executive Officer (incorporated by reference to Exhibit 10.38 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2008; Commission File No. 001-01011). | |
10.35* | Amendment dated December 21, 2012 to the Amended and Restated Employment Agreement dated as of December 22, 2008 between the Registrant and the Registrant’s President and Chief Executive Officer (incorporated by reference to Exhibit 10.31 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012; Commission File No. 001-01011). | |
10.36 | Form of Non-Qualified Stock Option Agreement between the Registrant and the Registrant’s President and Chief Executive Officer. | |
10.37 | Form of Restricted Stock Unit Agreement between the Registrant and the Registrant’s President and Chief Executive Officer. | |
10.38* | Amendment dated January 22, 2015 to Nonqualified Stock Option Agreements between the Registrant and the Registrant’s President and Chief Executive Officer (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K dated January 20, 2015; Commission File No. 001-01011). | |
10.39* | Change in Control Agreement dated December 22, 2008 between the Registrant and the Registrant’s Executive Vice President and Chief Financial Officer (incorporated by reference to Exhibit 10.39 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2010; Commission File No. 001-01011). | |
10.40* | Amendment dated as of December 31, 2012 to the Change in Control Agreement dated December 22, 2008 between the Registrant and the Registrant’s Executive Vice President and Chief Financial Officer (incorporated by reference to Exhibit 10.32 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012; Commission File No. 001-01011). |
10.41* | Change in Control Agreement dated December 22, 2008 between the Registrant and the Registrant’s Executive Vice President and President of CVS/caremark (incorporated by reference to Exhibit 10.33 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012; Commission File No. 001-01011). | |
10.42* | Amendment dated as of December 31, 2012 to the Change in Control Agreement dated December 22, 2008 between the Registrant and the Registrant’s Executive Vice President and President of CVS/caremark; incorporated by reference to Exhibit 10.34 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012 (Commission File No. 001-01011). | |
10.43 | Change in Control Agreement dated December 22, 2008 between the Registrant and the Registrant’s Executive Vice President and President of CVS/pharmacy. |
10.44 | Amendment dated as of December 31, 2012 to the Change in Control Agreement between the Registrant and the Registrant’s Executive Vice President and President of CVS/pharmacy. | |
10.45* | Change in Control Agreement dated December 1, 2008 between the Registrant and the Registrant’s Executive Vice President and Chief Medical Officer (incorporated by reference to Exhibit 10.43 of the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013; Commission File No. 001-01011). | |
13 | Portions of the 2014 Annual Report to Stockholders of CVS Health Corporation, which are specifically designated in this Form 10-K as being incorporated by reference. | |
21 | Subsidiaries of the Registrant. | |
23 | Consent of Ernst & Young LLP. | |
31.1 | Certification by the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
31.2 | Certification by the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
32.1 | Certification by the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
32.2 | Certification by the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
101 | The following materials from the CVS Health Corporation Annual Report on Form 10-K for the year ended December 31, 2014 formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Statements of Income, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows and (iv) related notes. |
CVS HEALTH CORPORATION | ||
Date: February 10, 2015 | By: | /s/ DAVID M. DENTON |
David M. Denton | ||
Executive Vice President and Chief Financial Officer |
Signature | Title(s) | Date | ||
/s/ RICHARD M. BRACKEN | Director | February 10, 2015 | ||
Richard M. Bracken | ||||
/s/ C. DAVID BROWN II | Director | February 10, 2015 | ||
C. David Brown II | ||||
/s/ EVA C. BORATTO | Senior Vice President - Controller and Chief Accounting Officer (Principal Accounting Officer) | February 10, 2015 | ||
Eva C. Boratto | ||||
/s/ DAVID M. DENTON | Executive Vice President and Chief Financial Officer (Principal Financial Officer) | February 10, 2015 | ||
David M. Denton | ||||
/s/ NANCY-ANN M. DEPARLE | Director | February 10, 2015 | ||
Nancy-Ann M. DeParle | ||||
/s/ DAVID W. DORMAN | Chairman of the Board and Director | February 10, 2015 | ||
David W. Dorman | ||||
/s/ ANNE M. FINUCANE | Director | February 10, 2015 | ||
Anne M. Finucane | ||||
/s/ LARRY J. MERLO | President and Chief Executive Officer (Principal Executive Officer) and Director | February 10, 2015 | ||
Larry J. Merlo | ||||
/s/ JEAN-PIERRE MILLON | Director | February 10, 2015 | ||
Jean-Pierre Millon | ||||
/s/ RICHARD J. SWIFT | Director | February 10, 2015 | ||
Richard J. Swift | ||||
/s/ WILLIAM C. WELDON | Director | February 10, 2015 | ||
William C. Weldon | ||||
/s/ TONY L. WHITE | Director | February 10, 2015 | ||
Tony L. White |
ARTICLE I – INTRODUCTION | 1 |
1.01 | NAME OF PLAN 1 |
1.02 | PURPOSE OF PLAN 1 |
1.03 | “TOP HAT” PENSION BENEFIT PLAN 1 |
1.04 | FUNDING 1 |
1.05 | EFFECTIVE DATE 1 |
1.06 | ADMINISTRATION 1 |
1.07 | NUMBER AND GENDER 1 |
1.08 | HEADINGS 1 |
ARTICLE II – DEFINITIONS | 2 |
ARTICLE III – ELIGIBILITY AND PARTICIPATION | 6 |
3.01 | ELIGIBILITY 6 |
3.02 | COMMENCEMENT OF PARTICIPATION 6 |
3.03 | TERMINATION OF PARTICIPATION 6 |
ARTICLE IV – DEFERRALS & COMPANY CONTRIBUTIONS | 7 |
4.01 | DEFERRAL AMOUNTS 7 |
4.02 | FILING REQUIREMENTS OF DEFERRED COMPENSATION ELECTIONS 7 |
4.03 | MODIFICATION OR REVOCATION OF ELECTION BY PARTICIPANT 8 |
4.04 | COMPANY CONTRIBUTIONS AND OTHER DEFERRALS 9 |
4.05 | DEFERRAL AND CONTRIBUTION TIMING 10 |
ARTICLE V – ACCOUNTS | 11 |
5.01 | ESTABLISHMENT OF BOOKKEEPING ACCOUNTS 11 |
5.02 | SUBACCOUNTS 11 |
5.03 | HYPOTHETICAL NATURE OF ACCOUNTS 11 |
5.04 | VESTING 11 |
5.05 | DEFERRAL CREDITING OPTIONS 11 |
5.06 | HYPOTHETICAL GAINS OR LOSSES 12 |
ARTICLE VI – DISTRIBUTION OF ACCOUNT | 13 |
6.01 | NORMAL DISTRIBUTIONS 13 |
6.02 | FORM OF PAYMENT 14 |
6.03 | DISABILITY DISTRIBUTIONS 14 |
6.04 | DISTRIBUTIONS IN THE EVENT OF DEATH 14 |
6.05 | DISTRIBUTIONS UPON TERMINATION OF EMPLOYMENT OTHER THAN RETIREMENT, DEATH OR DISABILITY 15 |
6.06 | CHANGE OF DISTRIBUTION ELECTION 15 |
6.07 | ACCOUNT VALUATION UPON A DISTRIBUTION 16 |
6.08 | DESIGNATION OF BENEFICIARY 16 |
6.09 | UNCLAIMED BENEFITS 17 |
6.10 | HARDSHIP WITHDRAWALS 17 |
6.11 | CHANGE IN CONTROL 17 |
6.12 | DISTRIBUTION OF GRANDFATHERED DEFERRAL ACCOUNT AND THE GRANDFATHERED COMPANY ACCOUNT 17 |
ARTICLE VII – ADMINISTRATION | 18 |
7.01 | PLAN COMMITTEE 18 |
7.02 | GENERAL POWERS OF ADMINISTRATION 18 |
7.03 | COSTS OF ADMINISTRATION 18 |
7.04 | INDEMNIFICATION OF PLAN COMMITTEE 18 |
7.05 | COMPLIANCE 18 |
ARTICLE VIII – CLAIMS PROCEDURE | 20 |
8.01 | CLAIMS 20 |
8.02 | CLAIM DECISION 20 |
8.03 | REQUEST FOR REVIEW 20 |
8.04 | REVIEW OF DECISION 20 |
ARTICLE IX – MISCELLANEOUS | 21 |
9.01 | NOT CONTRACT OF EMPLOYMENT 21 |
9.02 | NON-ASSIGNABILITY OF BENEFITS 21 |
9.03 | WITHHOLDING 21 |
9.04 | AMENDMENT AND TERMINATION 21 |
9.05 | COMPLIANCE WITH SECURITIES AND OTHER LAWS 21 |
9.06 | NO TRUST CREATED 22 |
9.07 | UNSECURED GENERAL CREDITOR STATUS OF EMPLOYEE 22 |
9.08 | PAYMENT TO MINORS AND INCOMPETENTS 22 |
9.09 | ACCELERATION OF OR DELAY IN PAYMENTS 22 |
9.10 | SEVERABILITY 23 |
9.11 | GOVERNING LAWS 23 |
9.12 | BINDING EFFECT 23 |
APPENDIX A | 24 |
2.01 | Account means the Company Account, Deferral Account, Grandfathered Company Account, and the Grandfathered Deferral Account maintained by the Corporation on behalf of each Participant pursuant to this Plan. |
2.02 | Affiliate means any entity, that together with the Corporation, would be treated as a single employer under Section 414(b) or (c) of the Code. |
2.03 | Annual Cash Incentive means the amount awarded to a Participant in cash for a Plan Year under a regular (annual or quarterly) incentive plan (other than an exceptional performance award program or a one-time incentive plan or program) maintained by the Corporation or an Affiliate, and any other amount otherwise included in Annual Cash Incentive for purposes of the Plan under rules as are adopted by the Committee. |
2.04 | Annual Cash Incentive Deferral means the amount of a Participant’s Annual Cash Incentive which a Participant elects to have withheld on a pretax basis from his Annual Cash Incentive and credited to his Deferral Account pursuant to this Plan. |
2.05 | Base Salary means the base rate of cash compensation paid by the Corporation or an Affiliate to or for the benefit of a Participant for services rendered or labor performed while a Participant, including base pay a Participant could have received in cash in lieu of: |
(a) | deferrals pursuant to this Plan; and |
(b) | any pre-tax contribution to be made on the Participant’s behalf to any qualified plan maintained by the Corporation or an Affiliate pursuant to a cash or deferred arrangement maintained by the Corporation or an Affiliate (as defined under Section 401(k) of the Code) or under any cafeteria plan (as defined under Section 125 of the Code) or under a qualified transportation fringe (as defined under Section 132(f) of the Code). |
2.06 | Base Salary Deferral means the amount of a Participant’s Base Salary which the Participant elects to have withheld on a pretax basis from his Base Salary and credited to his Deferral Account pursuant to this Plan. |
2.07 | Beneficiary means the person or persons designated by the Participant in accordance with the provisions of Section 6.08 to receive the amounts, if any, payable under the Plan upon the death of the Participant. |
2.08 | Board means the Board of Directors of the Corporation. |
2.09 | Change in Control means “Change in Control” as such term is defined in the Universal 409A Definition Document. |
2.10 | Code means the Internal Revenue Code of 1986, as amended. |
2.11 | Commissions mean the amount of a Participant’s sales commissions or other commissions payable under a sales commissions or other commissions plan maintained by the Corporation or an Affiliate. (Sales commissions for purposes of the Plan shall mean sales commissions (as defined in Treas. Reg. Section 1.409A-2(a)(12)(i) and any subsequent guidance) and such sales commissions are considered to be earned in the taxable year of the Participant in which the sale occurs.) |
2.12 | Commissions Deferral means the amount of a Participant’s Commissions which a Participant elects to have withheld on a pre-tax basis from his Commissions and credited to his Deferral Account pursuant to this Plan. |
2.13 | Committee means the Management Planning and Development Committee of the Board. |
2.14 | Company Account means the bookkeeping account (or subaccount(s) thereof) maintained for each Participant to record the amounts of Company Contributions that are either (i) credited on his behalf under Section 4.04 on or after January 1, 2005 or (ii) were credited on his behalf under Section 4.04 prior to January 1, 2005, but become vested on or after January 1, 2005, as adjusted pursuant to Section 5.06. |
2.15 | Company Contribution means the amount, as determined by the Company on an annual basis based on the provisions of this Plan, which is credited on the Participant’s behalf by the Company to his Company Account pursuant to the provisions of Section 4.04(a) of the Plan. |
2.16 | Corporation means CVS Caremark Corporation. References in the Plan to CVS Caremark Corporation shall be deemed to include successors to CVS Caremark Corporation. |
2.17 | CVS Caremark Retention Payment means the amount granted to an Eligible Executive, as defined in and provided for under the provisions of the employment term sheet agreement entered into between the Corporation or an Affiliate and said eligible executive, as a former employee of Caremark Rx, Inc., in connection with the merger involving Caremark, Rx, Inc. and the Corporation. |
2.18 | Deferrals mean the amount of deferrals credited to a Participant pursuant to Section 4.01. |
2.19 | Deferral Account means the bookkeeping account (or subaccount(s) thereof) maintained for each Participant to record (i) the amount of Base Salary, CVS Caremark Retention Payment and/or Annual Cash Incentive or Commissions the Participant defers pursuant to Section 4.01 or (ii) the amount of LTIP deferrals the Participant elects to defer pursuant to Section 4.04(b), on or after January 1, 2005, as adjusted pursuant to Section 5.06. |
2.20 | Deferred Compensation Election means the written election including any amendments, attachments and appendices thereto as prescribed by the Plan Committee, regardless of how it may be titled, under which the Participant agrees to defer a portion of his Base Salary and/or Annual Cash Incentive or Commissions under the Plan (or any other cash remuneration payable to a Participant that he may elect to defer under the provisions of this Plan, including but not limited to LTIP cash awards). This election is made by the Participant and constitutes the agreement entered |
2.21 | Effective Date means January 1, 1997. |
2.22 | Elective Deferrals means Elective Deferrals as defined in Section 3.02 of Future Fund. |
2.23 | Eligible Executive means an Executive who is eligible to participate in the Plan as provided in Section 3.01(a). |
2.24 | Employee means any common-law employee of the Corporation or an Affiliate which has been authorized by the Committee to participate in the Plan. |
2.25 | ERISA means the Employee Retirement Income Security Act of 1974, as amended. |
2.26 | Executive means an Employee whose Base Salary (determined on the basis of a maximum 40- hour work week) equals or exceeds $150,000 (as adjusted from time to time by the Committee). |
2.27 | Future Fund means the 401(k) Plan and the Employee Stock Ownership Plan of CVS Caremark Corporation and Affiliated Companies. |
2.28 | Grandfathered Company Account means the bookkeeping account (or subaccount(s)) maintained for each Participant to record the amount of Company Contributions credited on a Participant’s behalf under Section 4.04 prior to January 1, 2005, which were vested as of December 31, 2004, adjusted as provided in Section 5.06. |
2.29 | Grandfathered Deferral Account means the bookkeeping account (or subaccount(s)) maintained for each Participant to record (i) the amount of Base Salary and/or Annual Cash Incentive or Commissions deferred in accordance with Section 4.01 or (ii) the amount of LTIP deferrals deferred in accordance with Section 4.04, prior to January 1, 2005, adjusted pursuant to Section 5.06. |
2.30 | Lost Matching Contributions means the amounts credited on a Participant’s behalf to his Company Account pursuant to the provisions of Section 4.04(a). |
2.31 | Participant means each Eligible Executive participating in the Plan pursuant to Article III who is credited with an amount under Article IV. |
2.32 | Plan means the CVS Caremark Deferred Compensation Plan, as amended from time to time. |
2.33 | Plan Committee means the administrative committee appointed pursuant to Section 7.01 to administer the Plan. |
2.34 | Plan Year means each calendar year ending on December 31. |
2.35 | Qualified Future Fund Matching Contribution means the total of all matching contributions made (or that would have been made) by the Corporation or an Affiliate with respect to a Plan Year for the benefit of a Participant under and in accordance with the terms of the Future Fund. |
2.36 | Retirement means Termination of Employment with the Corporation and all Affiliates on or after (i) age 55 and the completion of ten or more Years of Service or, if earlier, (ii) age 60 and the completion of five or more Years of Service. |
2.37 | Specified Employee means “Specified Employee” as such term is defined in the Universal 409A Definition Document. |
2.38 | Specific Future Year means a calendar year in the future voluntarily elected by a Participant to begin distribution of Accounts (or subaccount(s) thereof) pursuant to this Plan. |
2.39 | Termination of Employment means “termination of employment” as such term is defined in the Universal 409A Definition Document. |
2.40 | Valuation Date means each business day on which the New York Stock Exchange is open for business, or such other day as the Plan Committee may determine. |
2.41 | Years of Service means Vesting Service as defined in the Future Fund. |
(a) | An Employee who is an Eligible Executive on October 1st of a calendar year (or such other date in the calendar year as designated by the Plan Committee) shall be an Eligible Executive with respect to the Plan Year following such calendar year and thereby eligible to participate in this Plan and execute a Deferred Compensation Election authorizing Deferrals under the Plan with respect to a particular Plan Year. The Committee or the Plan Committee, may, in its sole discretion, designate other key employees of the Corporation or an Affiliate which has been authorized by the Committee to participate in the Plan who are members of a select group of management or highly compensated employees as eligible to participate in the Plan. |
(b) | Notwithstanding any Plan provision to the contrary, Employees must also be subject to the income tax laws of the United States in order to be eligible for participation in the Plan. |
(c) | Subject to the provisions of Section 3.03 below and Section 4.01, an Eligible Executive shall remain eligible to continue participation in the Plan for each Plan Year following his initial year of participation in the Plan. |
(a) | Participation shall cease when all benefits to which a Participant is entitled to hereunder are distributed to him. |
(b) | Subject to the provisions of Section 4.03, a Participant shall only be eligible to have Deferrals credited on his behalf in accordance with Article IV for as long as he remains an Eligible Executive. |
(c) | If a former Participant who has incurred a Termination of Employment with the Corporation and all Affiliates and whose participation in the Plan ceased under Section 3.03(a) is reemployed as an Eligible Executive, the former Participant may again become a Participant in accordance with the provisions of Section 3.01. |
(a) | Subject to the following provisions of this Article IV, an Eligible Executive may defer for any Plan Year, (i) up to 50% of Base Salary otherwise earned and payable in that Plan Year, and/or (ii) up to 100% of Annual Cash Incentive otherwise earned in that Plan Year and payable in that Plan Year or in the first calendar quarter of the following Plan Year or (iii) up to 100% of Commissions otherwise earned in that Plan Year and payable in that Plan Year or in the first calendar quarter of the following Plan Year. The Plan Committee may, as it deems appropriate, establish maximum or minimum limits on the amounts which may be deferred for a Plan Year and/or the times of such Deferred Compensation Elections. An Eligible Executive shall be given advance notice of any such limits. |
(b) | Deferrals under this Plan shall be calculated with respect to the gross cash compensation payable to the Participant prior to any deductions (e.g., 401(k) deferrals) or withholdings. However, the Deferrals shall be reduced by the Plan Committee as necessary if it is later determined, after Deferrals are made under this Plan and after additional deduction of all required income and employment taxes, 401(k) and other employee benefit deductions, and other deductions required by law, that all such total deferrals will exceed 100% of the available cash compensation of the Participant. Changes to payroll withholdings that affect the amount of compensation being deferred to the Plan shall be allowed only to the extent permissible under Code Section 409A. |
(a) | A Participant’s Deferred Compensation Election for a Plan Year shall become irrevocable as of the close of business on the date established by the Plan Committee, but not later than the last day of the calendar year preceding the Plan Year in which such Base Salary, Annual Cash Incentive or Commissions applicable to that election is earned. Such Deferred Compensation Election shall become effective as of the first day of the Plan Year in which such Base Salary and/or Annual Cash Incentive or Commissions is earned. |
(b) | If a Participant’s Deferred Compensation Election applicable to his Base Salary and/or Annual Cash Incentive or Commissions is cancelled for a Plan Year, he will not be permitted to elect to make Deferrals again until the next Plan Year. |
(c) | If a Participant ceases to be an Eligible Executive after the date a Deferred Compensation Election becomes effective but continues to be employed by the Corporation or an Affiliate, he shall continue to be a Participant and his Deferred Compensation Election currently in effect shall remain in force, but such Participant shall not be eligible to make any futher Deferred Compensation Elections until such time as he shall once again become an Eligible Executive. |
(d) | Notwithstanding anything in this Plan to the contrary, if Eligible Executive: |
(i) | receives a withdrawal of deferred cash contributions on account of hardship from any plan which is maintained by the Corporation or an Affiliate and which meets the requirements of Section 401(k) of the Internal Revenue Code (or any successor thereto); and |
(ii) | is precluded from making contributions to such 401(k) plan for at least 6 months after receipt of the hardship withdrawal, |
(a) | Company Contributions - Restoration of Lost Matching Contribution. The amount of Lost Matching Contributions credited under the Plan on a Participant’s behalf each calendar year shall be equal to (i) minus (ii) where: |
(i) | is the total Qualified Future Fund Matching Contribution that would have been allocated on the Participant’s behalf under Future Fund, without giving effect to any reductions or limitations required by Sections 401(a)(17), 401(k), 402(g) and/or 415 of the Code, for the Plan Year based on the aggregate of the Participant’s Elective Deferrals to Future Fund, his deferrals to any other qualified defined contribution plan maintained by the Corporation or an Affiliate, and his Deferral under Section 4.01 for the Plan Year, disregarding, in all cases, any deferrals made with respect to Base Salary, Annual Cash Incentives and Commissions otherwise payable prior to the first payroll period commencing in the month following date the Participant’s completion of one Year of Service; and |
(ii) | if the Participant is eligible to contribute to Future Fund during the Plan Year, the actual matching contributions made on the Participant’s behalf to Future Fund or any other qualified defined contribution plan maintained by the Corporation or any Affiliate for that Plan Year. However, if the Participant is not eligible to contribute to Future Fund during the Plan Year but is eligible to contribute to the CareSave 401(k) Retirement Savings Plan for Employees of Caremark Rx, Inc. during that Plan Year, the amount under this clause (ii) shall equal the maximum amount of matching contributions the Participant would have received under the provisions of Future Fund for that Plan Year had he been eligible to contribute to Future Fund during that Plan Year, based on his Base Salary and/or Annual Cash Incentive or Commissions otherwise earned and payable in that Plan Year, and his contributions to the CareSave 401(k) Retirement Savings Plan for Employees of Caremark Rx, Inc. for that Plan Year had been made to Future Fund. |
(b) | LTIP Deferrals. |
(c) | Cash Retention Award Deferrals. |
(b) | Notwithstanding the foregoing, any Company Contributions, made with respect to a Plan Year beginning on or after January 1, 2005, adjusted as provided in Article V, shall be distributed pursuant to the Participant’s distribution election made with respect to his Base Salary Deferrals for that Plan Year. In the event a Participant has not made a Base Salary Deferral in that Plan Year, such distribution shall be made pursuant to his distribution election made with respect to Annual Cash Incentive or Commissions Deferral for that Plan Year, if any; otherwise, such distribution shall be made at Retirement. |
(c) | The distribution of the portion of a Participant’s Deferral or Company Account (or subaccount(s)) that is deferred to Retirement under paragraph (a)(i) of this Section, adjusted as provided in Article V, shall commence on the first business day in January following his Retirement, pursuant to the provisions of Section 6.02, provided, however, that with respect to a Participant who is a Specified Employee as of the date of his Retirement, payment of any portion of his Deferral or Company Account (or any subaccount(s) thereof) will be delayed until the first day of the seventh month following the date such Retirement occurs. |
(d) | A Participant shall not change his normal distribution election under this Section 6.01, except as otherwise provided in Section 6.06 below. |
(a) | Subject to the limitations set forth in the Article VI, Normal Distributions will be made in annual (or quarterly, if the election was made prior to October 1, 2008) installments, as elected by the Participant, for up to, and including, fifteen (15) years (10 years for an election made after October 1, 2008). The initial installment of an annual or quarterly payment stream will begin as of the first business day in January following the Participant’s date of Retirement or of the Specific Future Year in accordance with the provisions of set forth in Section 6.01. Subsequent annual or quarterly payments will be as of the first business day of each subsequent calendar year of the installment period. Notwithstanding the foregoing, effective as of October 1, 2008, a Participant may not elect either quarterly installments or installments in excess of 10 years. |
(b) | Normal Distributions made pursuant to Section 6.01 will occur when and how a Participant elects to receive payment at the time of his Deferred Compensation Election. A Participant may choose different forms of payment with respect to each Deferred Compensation Election. Any Company Contributions made with respect to a Plan Year beginning on or after January 1, 2005, adjusted pursuant to Article V, shall be distributed pursuant to the Participant’s form of payment election made with respect to his Base Salary Deferral for that year. If the Participant has not made a Base Salary Deferral in that year, the portion of his Company Account attributable to such Company contributions will be distributed in accordance with his form of payment election with respect to his Annual Cash Incentive or Commissions Deferrals for that year, if any; otherwise payment will be made in a lump sum payment. In the absence of an election of the form of payment by a Participant on a Deferred Compensation Election, the portion of the Participant’s Account deferred pursuant to that Deferred Compensation Election, adjusted pursuant to the provisions of Article V, shall be paid in a single lump sum. |
(c) | A Participant shall not change his form of payment election, except as otherwise provided in Section 6.06 below. |
6.05 | Distributions Upon Termination of Employment Other Than Retirement, Death or Disability |
(a) | In accordance with such procedures as the Plan Committee may prescribe, a Participant may elect to change his Specific Future Year election under Section 6.01(ii) (or an Interium Distribution date election applicable to a portion of his Deferral Account or Company Account made pursuant to the provisions of the Plan as in effect prior to Decemeber 31, 2008) to a later Specific Future Year (or, if applicable, a later Interium Distribution date) by duly completing, executing and filing with the Plan Committee a new Specific Future Year election (or Interium Distribution date election) applicable to such deferrals, subject to the following limitations: |
(i) | such election must be made at least 12 months prior to the Specific Future Year (or Interium Distribution date) then in effect with respect to that portion of his Deferral or Company Account (or subaccount(s) thereof), and such election will not become effective until at least 12 months after the date on which the election is made; and |
(ii) | the new Specific Future Year (or Interium Distribution date) shall be a calendar year that is not less than five (5) years from the Specific Future Year (or Interium Distribution date) then in effect. |
(b) | In accordance with such procedures as the Plan Committee may prescribe, a Participant may elect to delay the payment of a portion of his Deferral or Company Account (or any subaccount(s) thereof) scheduled to be paid at his Retirement to his Retirement plus 5 calendar years by duly completing, executing and filing with the Plan Committee a new Retirement election applicable to such deferrals; provided, however such election shalll not become effective until at least 12 months after the date on which the election is made. |
(c) | In accordance with such procedures as the Plan Committee may prescribe, a Participant may elect to change the form of payment election under Section 6.02 applicable to his Normal Distribution under Section 6.01(i) or (ii) by duly completing, executing and filing with the Plan Committee a new form of payment election applicable to such deferrals, subject to the following limitations: |
(i) | such election must be made at least 12 months prior to the Specific Future Year then in effect with respect to that portion of his Deferral or Company Account (or subaccount(s) thereof), and such election will not become effective until at least 12 months after the date on which the election is made; and |
(ii) | the Normal Distribution of that portion of his Deferral or Company Account (or subaccount(s) thereof) shall be deferred for five years from the date such amount would otherwise have been paid absence this election. |
(d) | It is the Corporation's intent that the provisions of Sections 6.06(a), (b) and (c) comply with the subsequent election provisions in Code Section 409A(a)(4)(C), related regulations and other applicable guidance, and this Section 6.06 shall be interpreted accordingly. The Plan Committee may impose additional restrictions or conditions on a Participant's ability to make an election pursuant to this Section 6.06(a). For avoidance of doubt, a Participant may not elect to alter the distribution of any portion of his Deferral or Company Accounts (or any subaccount(s) thereof) from Retirement to a Specific Future Year or, except as provided in paragraph (a) above, from a Specific Future Year to Retirement. |
(e) | Transition Rules. Notwithstanding anything in the Plan to the contrary, the Plan Committee may, in its discretion and subject to such terms and conditions as it may from time to time prescribe, allow Participants to change the time of payment or portion of payment of all or a portion of their Deferral or Company Accounts prior to January 1, 2009 in accordance with applicable transition relief provided with respect to Code Section 409A, dated regulations and other applicable guidance. |
(a) | The specific reason or reasons for such denial; |
(c) | A description of any additional material or information necessary for the Claimant to perfect their claim and an explanation why such material or such information is necessary; |
(d) | Appropriate information as to the steps to be taken if the Claimant wishes to submit the claim for review; and |
(e) | The time limits for requesting a review under this Section. |
• | Client Relationship and Loyalty Survey (weight = 50%) |
• | Mail Service Pharmacy and Customer Care Survey (weight = 30%) |
• | Specialty Pharmacy Satisfaction Survey (weight = 20%) |
Measurement | Percent Weight | Measurement Tool | Achievement Measured Against | Modifier |
Operating Profit | 80% | Earnings Before Interest and Taxes (“EBIT”) | 2014 EBIT Goal | CEO & Committee Discretion (1) Financial Adjustments |
PBM Client Satisfaction | 10% | Client Relationship and Loyalty, Customer Care, Mail Service and Specialty Surveys | 2014 PBM Client Satisfaction Target | Operating Profit Funding |
Retail Customer Service | 10% | myCustomer Service Scorecard | 2014 myCustomer Experience Target | Operating Profit Funding |
• | Corp VPs and above (including BPC): 25% of MIP award based on SGI results |
• | Initiative Leaders and Members: 50% based on SGI results, and 50% on other objectives |
1. | If an Eligible Participant is hired or returns to work from an authorized leave of absence on or before the 15th of the month, the full month will be included in the incentive calculations. |
2. | If an Eligible Participant is hired or returns to work from an authorized leave of absence after the 15th of the month, then the full month will be excluded from the incentive calculations. |
3. | If an Eligible Participant’s employment is terminated on or before the 15th of the month and the employee is eligible for a prorated award under the Plan, then the full month will be excluded from incentive calculations. |
4. | If an Eligible Participant’s employment is terminated after the 15th of the month and the employee is eligible for a prorated award under the Plan, then the full month will be included in the incentive calculations. |
a. | An employee is hired as an Eligible Participant on September 14th. Because the Eligible Participant is actively employed prior to the 15th of September, the full month of September will be included in his/her prorated incentive award and the Eligible Participant will receive a prorated incentive award covering a total of four months. The award will be calculated using the Eligible Participant’s individual award opportunity target and base salary as of December 31st. |
b. | An Eligible Participant begins a personal leave of absence on June 3rd and returns to active status on July 22nd. Assuming the Eligible Participant was incentive eligible for the entire year, the months of June and July will be excluded from the Eligible Participant’s incentive award and the Eligible Participant will receive a prorated incentive award covering a total of 10 months. The award will be calculated using the Eligible Participant’s individual award opportunity target and base salary as of December 31st. |
VII. | Eligible Participant Status |
VIII. | Miscellaneous |
VI. | Payment of Awards |
1. | If a Participant’s employment is terminated on or before the 15th of the month and the employee is eligible for a prorated award under the Plan, then the full month will be excluded from incentive calculations. |
2. | If a Participant’s employment is terminated after the 15th of the month and the employee is eligible for a prorated award under the Plan, then the full month will be included in the incentive calculations. |
VII. | Retirement and Death |
VIII. | Miscellaneous |
C. | Compliance with Applicable Law |
G. | Interpretation |
Page | ||||
I. | Purpose and Status of the PEP. . . . . . . . . . . . . . . . . . . . . . . . . . | 1 | ||
II. | Eligibility . . . . . . . . . . . . . . . . . . . . . . . . . | 1 | ||
III. | Definitions . . . . . . . . . . . . . . . . . . . . . . . . | 1 | ||
IV. | Administration . . . . . . . . . . . . . . . . . . . . . . | 2 | ||
V. | Award . . . . . . . . . . . . . . . . . . . . . . . . . . | 3 | ||
VI. | Participation . . . . . . . . . . . . . . . . . . . . . . . | 3 | ||
VII. | Form of Participation . . . . . . . . . . . . . . . . . . . | 3 | ||
VIII. | Company Matching Investments . . . . . . . . . . . . . . | 4 | ||
IX. | Restrictions on Disposition of Participant Purchased Shares . . . | 4 | ||
X. | Dividends . . . . . . . . . . . . . . . . . . . . . . . . . . . .. | 4 | ||
XI. | Vesting and Settlement . . . . . . . . . . . . . . . . . . . . . . . . | 5 | ||
XII. | Option to Purchase Common Stock . . . . . . . . . . . . . | 5 | ||
XIII. | Termination of Employment . . . . . . . . . . . . . . . . | 6 | ||
XIV. | General Provisions . . . . . . . . . . . . . . . . . . . . | 8 | ||
XV. | Recoupment Policy . . . . . . . . . . . . . . . . . . . . | 10 | ||
(A) | Involuntary Termination of Participant’s Employment without Cause. |
(B) | Retirement of Participant. “Qualified Retirement” shall mean termination of employment after attainment of age fifty-five (55) with at least ten (10) years of continuous service, or attainment of age sixty (60) with at least five (5) years of continuous service, provided that: (i) if the Participant elects to terminate his or her employment voluntarily, the Participant has provided the Company with at least twelve (12) months advance notice of his or her retirement date or such other term of advance notice as is determined by the Chief Human Resources Officer of the Company; or (ii) if the Company elects to terminate the Participant’s employment, then such termination is without cause. As of the Participant’s retirement date, any Participant Purchased Shares shall not be subject to any transfer or sale restrictions, and any Participant Purchased RSUs shall settle on the Participant’s termination date. The Participant may exercise his or her vested Company Matching Option during the two-year period following the retirement date; any portion of the Company Matching Option which is not vested as of the retirement date shall be forfeited by the Participant as of the retirement date. Any Company Matching RSU or Company Matching Option that is not vested as of the retirement date shall be forfeited by the Participant. In the event the Participant’s termination of employment qualifies as a Qualified Retirement and the Participant also enters into a severance agreement with the Company, the terms of Section XIII(A) shall apply with respect to the settlement of Participant Purchased RSUs and the vesting and settlement of Company Matching RSUs and Company Matching Options. |
(C) | Disability of Participant. In the event a Participant ceases to be employed by the Company, or any subsidiary of the Company, by reason of total and permanent disability (as defined in the Company’s |
(D) | Death of Participant. In the event of a Participant’s death while employed by the Company or one of its subsidiaries, any Participant Purchased Shares or Participant Purchased RSUs shall not be subject to any transfer or sale restrictions. In addition, all Company Matching RSUs shall vest and settle on Participant’s date of death and Company Matching Options shall become immediately vested in full. The Company Matching Option may be exercised during the twelve (12) month period following the Participant’s date of death, or prior to the Company Matching Option expiration date, whichever occurs first, by the Participant’s executor, administrator, personal representative or any person or persons who acquired the Company Matching Option directly from the Participant by bequest or inheritance. At the end of said one-year time period, all rights with respect to any Company Matching Option that is unexercised shall terminate and the unexercised Company Matching Option shall be cancelled. |
(E) | Change In Control. In the event of a Termination Without Cause or a Constructive Termination Without Cause, in each case within the two-year period following a Change in Control, any Participant Purchased Shares or Participant Purchased RSUs shall not be subject to any transfer or sale restrictions. In addition, all of the Participant’s outstanding Company Matching RSUs shall vest and be settled and Company Matching Options that are not then vested will become immediately vested and exercisable. All other terms and conditions governing such Company Matching RSUs, Participant Purchased RSUs and Company Matching Options will be subject to the provisions of the Company’s 2010 ICP. |
(F) | Coordination of Provisions. Notwithstanding anything to the contrary above, to the extent that the circumstances of the termination of a Participant’s employment are within the description of more than one of the subparagraphs above in this Section XIII, each portion of a Participant’s Company Matching RSU or Company Matching Option under any Award shall be entitled to the more favorable treatment explicitly applicable to such portion of the Participant’s Company Matching RSU or Company Matching Option under the provisions of this Section XIII. For example, if a Participant qualifies as Qualified Retiree at the time of the Participant’s termination of employment but the Participant receives severance in connection with the Participant’s termination as described in Section XIII (A), the Participant’s unvested Matching Company Option shall continue to vest during the applicable severance period and any portion of the Company Matching Option that vests during the severance period shall be exercisable on or before the ninetieth (90th) day following the last day of the severance period, while any portion of the Participant’s Matching Company Option that vests as of the Retirement Date may be exercised during the two-year period following the Retirement Date. Similarly, by way of example, if a Participant experiences a termination of employment due to disability following a Change in Control, the treatment described in Section XIII (E) shall apply to the Participant’s Awards to the extent that such treatment is more favorable to the Participant than the treatment applicable under Section XIII (C). |
(G) | In any case, the settlement of Participant Purchased RSUs and Company Matching RSUs shall be subject to the settlement timing provisions of Section XIV(C)(ix) of the PEP. |
(i) | Adjustments. Participant Purchased Shares or RSUs, Company Matching RSUs, and Company Matching Options, and the terms and conditions relating thereto, shall be subject to adjustment in accordance with applicable sections of the 2010 ICP. |
(ii) | Nontransferability. Participant Purchased Shares or RSUs, Company Matching RSUs, Company Matching Options, and all rights relating thereto, shall not be transferable or assignable by a Participant, other than by will or the laws of descent and distribution (or pursuant to a beneficiary designation if and to the extent authorized by the Committee), and shall not be pledged, hypothecated, or otherwise encumbered in any way or subject to execution, attachment, or similar process, and any such attempt to transfer such rights shall be considered null and void by the Company. |
(iii) | Certain Other Terms. Additional terms applicable to Awards under the PEP are set forth in the 2010 ICP. |
(iv) | No Partnership Rights or Rights to Participate. A Participant’s participation in the PEP, investment in Participant Purchased Shares or RSUs, and grant of an Award under the PEP confers no rights as a partner of a partnership. No Participant has or will have any claim to participate in the PEP, except as selected by the Committee, and the Company will have no obligation to continue the PEP. |
(v) | Changes to the PEP. The Committee may amend, alter, suspend, discontinue or terminate the PEP without the consent of any Participant; provided, however, that, without the consent of an affected Participant, no such action shall materially and adversely affect the rights of such Participant with respect to an outstanding Award. |
(vi) | Limitation on Repurchase Obligation. All repurchases of Stock permitted to occur in the ordinary course pursuant to the terms established under the PEP are intended to qualify for the exemption from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) promulgated under the Exchange Act and, accordingly, such repurchases are authorized to occur with respect to all Awards under the PEP unless and until the repurchase rights and obligations relating to an Award are explicitly revoked by the Committee. |
(vii) | Agreements and Other Documents. The Committee shall specify agreements or other documents to evidence rights and obligations under the PEP. A form of agreement that may be used to evidence rights and obligations relating to Participant Purchased Shares and/or RSUs, Company Matching RSUs and Company Matching Options shall be provided to each Participant. |
(viii) | Governing Law. The validity, construction, and effect of the PEP, any rules and regulations and any award agreements or related documents hereunder shall be determined in accordance with the Delaware General Corporation Law, without giving effect to principles of conflicts of laws and applicable federal law. |
(ix) | Section 409A Compliance. The Participant Purchased RSUs and Company Matching RSUs under the PEP are intended to qualify as nonqualified deferred compensation awards which comply with the provisions of Section 409A and the regulations thereunder. The vesting dates shall be the dates fixed under the terms of the PEP as of the Grant Date, subject to acceleration only upon the following permissible events under Section 409A of the Code as specified under the PEP or as otherwise provided by the Committee in its sole discretion: the Participant’s death, the Participant’s qualifying disability (under Section XIII (C)) or a Change in Control (within the meaning of the 2010 ICP, which includes a definition of change in control that complies with Section 409A of the Code). Any portion of a Participant Purchased RSU and Company Matching RSU that has become vested in accordance with the terms of the PEP shall be settled as provided under the PEP on a date selected by the Company occurring prior to the 15th day of the third calendar month following the applicable vesting date. In the event that a Participant experiences a termination of employment and is granted severance and is therefore permitted to continue to vest in one or more installments of a Participant Purchased RSU or Company Matching RSU Award pursuant to Section XIII (A), such installments shall continue to be subject to settlement only after the vesting date originally applicable to such installments and during the settlement period set forth above in this Section XIV (C). In the event that the Committee exercises its sole discretion to waive the forfeiture provisions applicable to any Participant Purchased RSUs or Company Matching RSUs, those RSUs shall be settled at the same time that they would otherwise have been settled if they had vested in due course under the terms of the PEP and the applicable Award. Notwithstanding the foregoing or any other provision of the PEP or any Award to the contrary, to the extent necessary to comply with the requirements of Section 409A of the Code, any settlement amounts to which a Participant may become entitled under the PEP, which are subject to Section 409A of the Code (and not otherwise exempt from its application), that are payable within six months following the date of termination will be withheld until the first business day of the seventh (7th) month following the date of termination. To the extent any provisions of the PEP or any RSU does not comply with Section 409A of the Code, the Company and any affected Participant will make such changes with respect to such RSU as are mutually acceptable in order to comply with Section 409A of the Code. |
I. | Objectives and Summary |
II. | Administration |
III | PBRS Plan Year |
IV. | Eligibility |
a) | In General. Except as provided in paragraphs (ii)-(iv) below, if for any reason the employment of an Eligible Employee with the Company and any subsidiary of the Company terminates during a PBRS Plan Year, the Eligible Employee will not receive a PBRS Award for that PBRS Plan Year. |
b) | Retirement. If an Eligible Employee is at least age 55 and has a minimum of 10 years of service with CVS Health or a predecessor company/subsidiary or is at least age 60 and has a minimum of 5 years of service with CVS Health or a predecessor company/subsidiary and the Eligible Employee retires prior to the last day of the PBRS Plan Year, he or she may receive a PBRS Award. Such PBRS Award may be payable in cash at the same time PBRS Awards are made to other Eligible Employees and may be pro-rated for the number of full months (a partial month will be counted as a full month) during which the Eligible Employee was an active employee based on a full calendar year, provided he or she meets all other eligibility criteria for a PBRS Award. |
c) | Death or Disability. If an Eligible Employee dies or commences a long-term disability (as defined in the Company's LTD plan or by the Social Security Administrator), the Eligible Employee may receive a PBRS Award for the year in which the death or commencement of long-term disability occurs at the same time PBRS Awards are made to other Participants. Such PBRS Award will be pro-rated for the number of full months (a partial month will be counted as a full month) during which the Eligible Employee was an active employee based on a full calendar year and will (unless otherwise determined by the CEO or the Committee) be paid in cash based on the Eligible Employee’s base salary in effect at the time of death or commencement of long-term disability. PBRS Awards with respect to deceased Eligible Employees shall be paid to the Eligible Employee’s Beneficiary. |
d) | Other Terminations. In the sole discretion of the CEO or the Committee (as the case may be), an Eligible Employee who terminates employment with the Company and its subsidiaries prior to the last day of the PBRS Plan Year or prior to the Plan payout date for any reason other than retirement, death or long-term disability, as defined above in this section, may receive a PBRS Award. Such PBRS Award may be payable in cash at the same time PBRS Awards are made to other Participants |
V. | Plan Performance Measure |
VI. | Plan Payout |
A. | Target PBRS Award |
Consolidated Operating Profit (EBIT)(1) | PBRS Award Payout Percentage | |
% of EBIT Target | % of Target Payout | % of Base Salary |
>102.5% | 200% | 50% |
102.2% | 180% | 45% |
101.9% | 160% | 40% |
101.6% | 140% | 35% |
101.2% | 120% | 30% |
101.0% | 100% | 25% |
100.0% | 100% | 25% |
99.0% | 100% | 25% |
98.8% | 90% | 22.5% |
98.4% | 80% | 20.0% |
98.1% | 70% | 17.5% |
97.8% | 60% | 15.0% |
97.5% | 50% | 12.5% |
97.2% | 40% | 10.0% |
96.9% | 30% | 7.5% |
< 96.9% | 0% | 0.00% |
1. | For an employee residing in Illinois, Kansas, or North Carolina, you are hereby advised: |
2. | For an employee residing in Utah, you are hereby advised: |
3. | For an employee residing in Minnesota, you are hereby advised: |
Participant: | |
Employee ID: | |
Shares: | |
Option Price: |
(i) | 25% of the Option shall vest on the 1st anniversary of the Grant Date. |
(ii) | 25% of the Option shall vest on the 2nd anniversary of the Grant Date. |
(iii) | 25% of the Option shall vest on the 3rd anniversary of the Grant Date. |
(iv) | 25% of the Option shall vest on the 4th anniversary of the Grant Date. |
1. | Pursuant and subject to the provisions of the 2010 Incentive Compensation Plan, as amended (the “ICP”) of CVS Caremark Corporation (the “Company”), on the date set forth above (the “Grant Date”), the Company has awarded and hereby evidences the Restricted Stock Unit (“RSU”) Award to the person named below (the “Participant”), subject to the terms and conditions set forth and incorporated in this Restricted Stock Unit agreement (the “Agreement”). The ICP is hereby made a part hereof and Participant agrees to be bound by all the provisions of the ICP. Capitalized terms not otherwise defined herein shall have the meaning assigned to such term(s) in the ICP. On the Grant Date specified above, the Fair Market Value (the “FMV”), which is the Closing Price of the Company’s common stock on the Grant Date, of each RSU equals $XX.XX. |
Participant: | |
Employee ID: | |
RSUs (#): |
2. | Each RSU represents a right to a future payment of one share (“Share”) of Common Stock ($0.01 par value) of the Company, subject to required tax withholding. |
3. | (a) To the extent dividends are paid on Shares while the RSUs remain outstanding and prior to the Settlement Date (as defined below), subject to Section 5(b), Participant shall be entitled to receive a cash payment in an amount equivalent to the cash dividends with respect to the number of Shares covered by the RSUs; provided, however, that no dividends shall be payable with respect to any RSUs forfeited on or prior to the dividend record date. |
4. | Subject to the terms and conditions of the ICP and this Agreement and subject to Participant’s continued employment, Participant shall be entitled to receive (and the Company shall deliver to Participant) the Shares on the Vesting Date(s) set forth herein, , or as soon as administratively possible thereafter, unless delivery of the Shares has been deferred in accordance with Section 5 below (the date of such delivery of the Shares being hereafter referred to as the “Settlement Date”). Each “Vesting Date,” except as otherwise provided in Section 7, shall be in accordance with the schedule set forth below: |
5. | (a) In accordance with rules promulgated by the Management Planning and Development Committee of the Board of Directors (the “Committee”), Participant, to the extent eligible under the CVS Caremark Deferred Stock |
6. | Except as may be elected by Participant, on the Settlement Date the number of Shares to be delivered by the Company to Participant shall be reduced by the smallest number of Shares having a FMV at least equal to the dollar amount of Federal, state and local tax withholding required to be withheld by the Company with respect to such RSUs on such date. In lieu of having the number of Shares underlying the RSU reduced, Participant may elect to pay the Company for any amounts required to be withheld by the Company in connection with the vesting of the RSUs or delivery of the Shares pursuant to the Agreement. Such election may be made electronically at any time prior to the Settlement Date of the RSUs. |
7. | (a) Except as provided in Paragraphs 7 (b) – (g) below, if, for any reason, Participant’s employment with the Company and any subsidiary of the Company terminates, all RSUs not then vested in accordance with Section 4 above shall be immediately forfeited. |
8. | An RSU does not represent an equity interest in the Company and carries no voting rights. Participant shall have no rights of a shareholder with respect to the RSUs until the Shares have been delivered to Participant. |
9. | Neither the execution and delivery hereof nor the granting of the award evidenced hereby shall constitute or be evidence of any agreement or understanding, express or implied, on the part of the Company or its subsidiaries to employ Participant for any specific period. |
10. | Any notice required to be given hereunder to the Company shall be addressed to: CVS Caremark Corporation, Senior Vice President, Compensation & Benefits, One CVS Drive, Woonsocket, RI 02895. Any notice required to be given hereunder to Participant shall be addressed to such Participant at the address shown on the records of the Company, subject to the right of either party hereafter to designate, in writing, to the other, some other address. |
11. | All decisions and interpretations made by the Board of Directors or the Committee with regard to any question arising hereunder or under the ICP shall be binding and conclusive on all persons. In the event of any inconsistency between the terms hereof and the provisions of the ICP, the ICP shall govern. |
12. | The award of RSUs pursuant to this Agreement is expressly subject to and contingent upon the requirement that the Participant shall have fully executed and delivered to the Company the Restrictive Covenant Agreement provided by the Company; provided that the Company in its sole discretion may waive such requirement if Participant is currently a party to another agreement with the Company setting forth restrictive covenants, such as non-competition, non-disclosure, and/or non-solicitation obligations. The applicable agreement containing the restrictive covenants the Company requires in connection with this award is hereafter referred to as the “Restrictive Covenant Agreement”. |
1. | Pursuant and subject to the provisions of the 2010 Incentive Compensation Plan, as amended (the “ICP”) of CVS Caremark Corporation (the “Company”), on the date set forth above (the “Grant Date”), the Company has awarded and hereby evidences the Performance-Based Restricted Stock (“PBRS”) unit award (the “Award”) to the person named below (the “Participant”), subject to the terms and conditions set forth and incorporated in this PBRS Agreement (the “PBRS Agreement”), the Restricted Stock Units (“RSUs”) set forth below. The ICP is hereby made a part hereof and Participant agrees to be bound by all the provisions of the ICP. Capitalized terms not otherwise defined herein shall have the meaning assigned to such term(s) in the ICP. On the Grant Date specified above, the Fair Market Value (the "FMV") of a share of Stock equals $XX.XX, which is the closing price on such date. |
Participant | |
Employee Number | |
RSUs (#) |
2. | Each RSU represents a right to a future payment of one share (“Share”) of Common Stock ($0.01 par value) of the Company, subject to required tax withholding. |
3. | (a) To the extent dividends are paid on Shares while the RSUs remain outstanding and prior to the Settlement Date (as defined below), subject to Paragraph 5(b), Participant shall be entitled to receive a cash payment in an amount equivalent to the cash dividends with respect to the number of Shares covered by the RSUs; provided, however, that no dividends shall be payable with respect to any RSUs forfeited on or prior to the dividend record date. |
4. | Subject to the terms and conditions of the ICP and this PBRS Agreement, and subject to Participant’s continued employment, Participant shall be entitled to receive (and the Company shall deliver to Participant) the Shares within sixty (60) days following the Vesting Date(s) set forth herein, unless delivery of the Shares has been deferred in accordance with Paragraph 5 below (the date of such delivery of the Shares being hereafter referred to as the “Settlement Date”). Each “Vesting Date,” except as otherwise provided in Paragraph 7, shall be in accordance with the schedule set forth below: |
(b) | one-third (1/3) of the RSUs on the second anniversary of the Grant Date; and |
5. | (a) In accordance with rules promulgated by the Management Planning and Development Committee of the Board of Directors (the “Committee”), Participant, to the extent eligible under the CVS Caremark Deferred Stock Compensation Plan, may elect to defer delivery of Shares in settlement of RSUs covered by this PBRS Agreement. Any such deferred delivery date elected by Participant shall become the Settlement Date for purposes of this PBRS Agreement. |
6. | Except as may be elected by Participant, on Settlement Date the number of Shares to be delivered by the Company to Participant shall be reduced by the smallest number of Shares having a FMV at least equal to the dollar amount of Federal, state and local tax withholding required to be withheld by the Company with respect to such RSUs on such date. In lieu of having the number of Shares underlying the RSU reduced, Participant may elect to pay the Company for any amounts required to be withheld by the Company in connection with the vesting of the RSUs or delivery of the Shares pursuant to the PBRS Agreement. Such election may be made electronically at any time prior to the Settlement Date of the RSUs. |
7. | (a) Except as provided in Paragraphs 7 (b) – (g) below, if, for any reason, Participant’s employment with the Company and any subsidiary of the Company terminates, all RSUs not then vested in accordance with Paragraph 4 above, shall be immediately forfeited. |
8. | An RSU does not represent an equity interest in the Company and carries no voting rights. Participant shall have no rights of a shareholder with respect to the RSUs until the Shares have been delivered to Participant. |
9. | Neither the execution and delivery hereof nor the granting of the award evidenced hereby shall constitute or be evidence of any agreement or understanding, express or implied, on the part of the Company or its subsidiaries to employ Participant for any specific period. |
10. | Any notice required to be given hereunder to the Company shall be in writing addressed to: CVS Caremark Corporation, Senior Vice President, Compensation & Benefits, One CVS Drive, Woonsocket, RI 02895. Any notice required to be given hereunder to Participant shall be addressed to such Participant at the address shown on the records of the Company, subject to the right of either party hereafter to designate, in writing, to the other, some other address. |
11. | All decisions and interpretations made by the Board of Directors or the Committee with regard to any question arising hereunder or under the ICP shall be binding and conclusive on all persons. In the event of any inconsistency between the terms hereof and the provisions of the ICP, the ICP shall govern. |
12. | By accepting this Award, Participant acknowledges that a copy of the ICP has been made available for the Participant’s reference, and agrees to be bound by the terms and conditions set forth in this Agreement and the ICP as in effect from time to time. |
13. | By accepting this Award, Participant further acknowledges that the Federal securities laws and/or Company’s policies regarding trading in its securities may limit or restrict Participant’s right to buy or sell Shares, including without limitation, sales of Shares acquired in connection with RSUs. Participant agrees to comply with such Federal securities law requirements and Company policies as such laws and policies may be amended from time to time. |
14. | The company intends that this Agreement not violate any applicable provision of, or result in any additional tax or penalty under, Section 409A of the Internal Revenue Code of 1986 (the “Code”), as amended, and the regulations and guidance thereunder (collectively, “Section 409A”) and that to the extent any provisions of this PBRS Agreement do not comply with Section 409A the Company will make such changes as it deems reasonable in order to comply with Section 409A. In all events, the provisions of CVS Caremark Corporation’s 409A Universal Definitions Document are hereby incorporated by reference and, notwithstanding any other provision of the Plan or this PBRS Agreement to the contrary, to the extent required to avoid a violation of the applicable rules under Section 409A by reason of Section 409A(a)(2)(B)(i) of the Code, payment of any amounts subject to Section 409A shall be delayed until the first business day of the seventh month immediately following the date of termination of employment. For purposes of any provision of this PBRS Agreement providing for the payment of any amounts or benefits upon or following a termination of employment, references to the “termination of employment” (and corollary terms) shall be construed to refer to “separation from service” as determined under Section 409A. |
17. | This Agreement shall be fully effective only upon the Participant’s formal acceptance of the terms and conditions set forth above as required by the Company. |
(C) | Additional Transactions in Participant Accounts. |
(i) | Each Participant Purchased RSU and Company Matching RSU represents a right to a future payment of one share of Stock, subject to applicable tax withholding. |
(ii) | To the extent that dividends are declared and paid on shares of Stock while the Participant Purchased RSUs and Company Matching RSUs remain outstanding and prior to a Settlement Date (as defined below), the Company shall credit to Participant’s Purchased RSU account and Company Matching RSU account (as applicable) an additional number of Participant Purchased RSUs and Company Matching RSUs calculated by multiplying (a) the amount of dividend per share of Stock approved by the Company’s Board of Directors by (b) the number of Participant Purchased RSUs and Company Matching RSUs held by Participant on the dividend record date, and dividing the product by (c) the FMV of a share of Stock on such dividend payment date. |
(iii) | Provided, however, that if such dividend is paid prior to the Vesting Date of Participant Purchased RSUs and/or the Company Matching RSUs, as set forth in Section I (D) below, Participant shall not be entitled to any payment in respect of such dividend unless Participant is still employed by the Company on such dividend payment date. |
(iv) | Participant hereby agrees that, prior to the Settlement Date, the Company may withhold from the dividend equivalent amounts described to in Section I(C)(ii) amounts sufficient to satisfy the applicable tax withholding in respect of such dividend equivalent payments, as applicable. |
(i) | A “Settlement Date” shall mean the date shares of Stock are delivered to Participant pursuant to this Agreement. |
(ii) | Within fifteen (15) days following the earliest of the fifth (5th) anniversary of the Grant Date, Participant’s death, termination of employment due to Participant’s total and permanent disability (as defined in the Company’s Long-Term Disability Plan, or, if not defined in such plan, as defined by the Social Security Administration), or a Change in Control, Participant shall be entitled to receive and the Company shall deliver to Participant the total number of shares of Stock (giving effect to Sections I(C)(ii) and I(C)(iv)) underlying the Company Matching RSUs vested as of such date. Notwithstanding the foregoing, no shares of Stock shall be delivered upon termination of employment unless such termination of employment is considered a “separation from service” (within the meaning given of Treasury Regulation §1.409A-1(h) or successor guidance thereto). |
(iii) | Subject to the rules promulgated by the Committee, the terms of the CVS Health Deferred Stock Compensation Plan and Section 409A, Participant may elect to defer settlement of Participant Purchased or Company Matching RSUs covered by this Agreement. |
(i) | Prior to its expiration or termination, and except as otherwise provided herein, the Company Matching Option shall vest and may be exercised by Participant, provided Participant has maintained continuous employment with the Company or a subsidiary of the Company from the Grant Date until the applicable vesting date, within the following time limitations: |
a. | On or after three (3) years from the Grant Date, the Company Matching Option shall be vested and may be exercised as to one-third (1/3) of the shares of Stock subject to the Company Matching Option; |
b. | On or after four (4) years from the Grant Date, the Company Matching Option shall be vested and may be exercised as to an aggregate of two-thirds (2/3) of the shares of Stock subject to the Company Matching Option; and |
c. | On or after five (5) years from the Grant Date, the Company Matching Option shall be vested and may be exercised as to all of the shares of Stock subject to the Company Matching Option. |
(ii) | The Company Matching Option, subject to the provisions of the ICP, shall be exercised by submitting a request to exercise to the Company’s stock option administrator, in accordance with the Company’s current exercise policies and procedures, specifying the number of shares of Stock to be purchased, which number may not be less than one hundred (100) shares of Stock (unless the number of shares of Stock purchased is the total balance which is then exercisable). Unless the Company, in its discretion, establishes “cashless exercise” procedures and permits Participant entitled to exercise the Company Matching Option to utilize such “cashless exercise” procedures, Participant so exercising all or part of this Company Matching Option shall, at the time of exercise, tender to the Company |
(i) | the Company Matching RSUs shall be vested as of Participant’s employment termination date (which is the last day that the Participant is employed by the Company or any subsidiary of the Company) shall be equal to the number of Company Matching RSUs multiplied by the following fraction: (A) the numerator shall be the whole number of months elapsed since the Grant Date and (B) the denominator shall be sixty (60). For purposes of this calculation, the number of months in the numerator in sub-section (A) above shall include any partial month in which Participant has worked. For example, if the time elapsed between the Grant Date and the Separation Date is eight months and five days, the numerator in sub-section (A) above shall be nine. |
(ii) | the Company Matching Option shall be vested as of Participant’s employment termination date with respect to the number of shares of Stock subject to the Company Matching Option, multiplied by the following fraction: (A) the numerator shall be the whole number of months elapsed since the Grant Date and (B) the denominator shall be sixty (60). For purposes of this calculation, the number of months in the numerator in sub-section (A) above shall include any partial month in which Participant has worked. For example, if the time elapsed between the Grant Date and the Separation Date is eight months and five days, the numerator in sub-section (A) above shall be nine. |
(iii) | the vested portion of the Company Matching Option shall be exercisable during the twelve (12) month period following Participant’s employment termination date, as long as no government regulations or rules are violated by such accelerated vesting or exercise period; provided, however, that the Company Matching Option shall not be exercisable beyond its original term. |
(i) | In the event Participant’s termination of employment qualifies as a Qualified Retirement, Participant may exercise the Company Matching Option to the extent vested as of Participant’s retirement date at any time within two (2) years after Participant’s retirement date, but not beyond the original term of the Company Matching Option. To the extent unvested as of the retirement date, the Company Matching Option shall be forfeited. The Committee shall have the authority in its sole discretion to make any interpretations, determinations, and/or take any administrative actions with respect to whether Participant has experienced a Qualified Retirement. |
(ii) | Company Matching RSUs that are unvested as of the Participant’s retirement date are forfeited as of the retirement date. |
(iii) | In the event Participant’s termination of employment qualifies as a Qualified Retirement and Participant also enters into a severance agreement with the Company, the terms of Section III(D) shall apply with respect to the vesting and settlement of the Company Matching RSUs and the Company Matching Option. |
(i) | The Company has received from Participant a completed Election Form pursuant to which the Participant elects to invest the amount of $XXXXX in Participant Purchased Shares under the PEP. Participant’s Post-Tax Investment Date must occur within thirty (30) days of the Grant Date, and Participant must provide evidence to the Company of Participant’s purchase and ownership of the Participant Purchased Shares with a value as of the Post-Tax Investment Date equal to the elected investment amount in accordance with the PEP within thirty (30) days of the Grant Date. |
(ii) | Alternatively, Participant has demonstrated to the Company that he or she owns a sufficient number of shares of Stock in his or her own name, provided such shares of Stock are not held in a qualified 401(k) plan or in a nonqualified deferred stock compensation plan, having a FMV, on the Grant Date, at least equal to the amount elected by the Participant on the Election Form. In such event, such shares of Stock owned by Participant shall be designated as Participant Purchased Shares for purposes of this Agreement and the PEP. |
(iii) | Participant must provide to the Company on a semi-annual basis until the fifth (5th) anniversary of the Grant Date a brokerage statement or other evidence satisfactory to the Company that he or she has continued to maintain the number of Participant Purchased Shares as were owned by Participant on the Grant Date and/or the Post-Tax Investment Date. |
(iv) | In accordance with the PEP, if Participant disposes of Participant Purchased Shares prior to the fifth (5th) anniversary of the Grant Date, either in whole or in part, Participant will immediately forfeit a proportionate amount of the Company Matching RSUs and Company Matching Options that are unvested as of the date of such disposition. |
(i) | Each Company Matching RSU represents a right to a future payment of one share of Stock, subject to applicable tax withholding. |
(ii) | To the extent that dividends are declared and paid on shares of Stock while the Company Matching RSUs remain outstanding and prior to a Settlement Date (as defined below), the Company shall credit to Participant’s Matching RSU account (as applicable) an additional number of Company Matching RSUs calculated by multiplying (a) the amount of dividend per share of Stock approved by the Company’s Board of Directors by (b) the number of Company Matching RSUs held by Participant on the dividend record date and dividing the product by (c) the FMV of a share of Stock on such dividend payment date. |
(iii) | Provided, however, that if such dividend is paid prior to the Vesting Date of the Company Matching RSUs, as set forth in Section I (D) below, Participant shall not be entitled to any payment in respect of such dividend unless Participant is still employed by the Company on such dividend payment date. |
(iv) | Participant hereby agrees that, prior to the Settlement Date, the Company may withhold from the dividend equivalent amounts described in Section I(C)(ii) amounts sufficient to satisfy the applicable tax withholding in respect of such dividend equivalent payments, as applicable. |
(i) | A “Settlement Date” shall mean the date shares of Stock are delivered to Participant pursuant to this Agreement. |
(ii) | Within fifteen (15) days following the earliest of the fifth (5th) anniversary of the Grant Date, Participant’s death, termination of employment due to Participant’s total and permanent disability (as defined in the Company’s Long-Term Disability Plan, or, if not defined in such plan, as defined by the Social Security Administration), or a Change in Control, Participant shall be entitled to receive and the Company shall deliver to Participant the total number of shares of Stock (giving effect to Sections I(C)(ii) and I(C)(iv)) underlying the Company Matching RSUs vested as of such date. Notwithstanding the foregoing, no shares of Stock shall be delivered upon termination of employment unless such termination of employment is considered a “separation from service” (within the meaning given of Treasury Regulation §1.409A-1(h) or successor guidance thereto). |
(iii) | Subject to the rules promulgated by the Committee, the terms of the CVS Health Deferred Stock Compensation Plan and Section 409A, Participant may elect to defer settlement of Company Matching RSUs covered by this Agreement. |
(i) | Prior to its expiration or termination, and except as otherwise provided herein, the Company Matching Option shall vest and may be exercised by Participant, provided Participant has maintained continuous employment with the Company or a subsidiary of the Company from the Grant Date until the applicable vesting date, within the following time limitations: |
a. | On or after three (3) years from the Grant Date, the Company Matching Option shall be vested and may be exercised as to one-third (1/3) of the shares of Stock subject to the Company Matching Option; |
b. | On or after four (4) years from the Grant Date, the Company Matching Option shall be vested and may be exercised as to an aggregate of two-thirds (2/3) of the shares of Stock subject to the Company Matching Option; and |
c. | On or after five (5) years from the Grant Date, the Company Matching Option shall be vested and may be exercised as to all of the shares of Stock subject to the Company Matching Option. |
(ii) | The Company Matching Option, subject to the provisions of the ICP, shall be exercised by submitting a request to exercise to the Company’s stock option administrator, in accordance with the Company’s current exercise policies and procedures, specifying the number of shares of Stock to be purchased, which number may not be less than one hundred (100) shares of Stock (unless the number of shares of Stock purchased is the total balance which is then exercisable). Unless the Company, in its discretion, establishes “cashless exercise” procedures and permits Participant entitled to exercise the Company Matching Option to utilize such “cashless exercise” procedures, Participant so exercising all or part of this Company Matching Option shall, at the time of exercise, tender to the Company cash or cash equivalent for the aggregate exercise price of the shares of Stock Participant has elected to purchase or certificates for shares of Stock of the Company already owned by Participant for at least six (6) months with an aggregate FMV at least equal to the aggregate exercise price of the shares of Stock Participant has elected to purchase, or a combination of the foregoing. |
(i) | the Company Matching RSUs shall be vested as of Participant’s employment termination date (which is the last day that the Participant is employed by the Company or any subsidiary of the Company) shall be equal to the number of Company Matching RSUs multiplied by the following fraction: (A) the numerator shall be the whole number of months elapsed since the Grant Date and (B) the denominator shall be sixty (60). For purposes of this calculation, the number of months in the numerator in sub-section (A) above shall include any partial month in which Participant has worked. For example, if the time elapsed between the Grant Date and the Separation Date is eight months and five days, the numerator in sub-section (A) above shall be nine. |
(ii) | the Company Matching Option shall be vested as of Participant’s employment termination date with respect to the number of shares of Stock subject to the Company Matching Option multiplied by the following fraction: (A) the numerator shall be the whole number of months elapsed since the Grant Date and (B) the denominator shall be sixty (60). For purposes of this calculation, the number of months in the numerator in sub-section (A) above shall include any partial month in which Participant has worked. For example, if the time elapsed between the Grant Date and the Separation Date is eight months and five days, the numerator in sub-section (A) above shall be nine. |
(iii) | the vested portion of the Company Matching Option shall be exercisable during the twelve (12) month period following Participant’s employment termination date, as long as no government regulations or rules are violated by such accelerated vesting or exercise period; provided, however, that the Company Matching Option shall not be exercisable beyond its original term. |
(i) | In the event Participant’s termination of employment qualifies as a Qualified Retirement, Participant may exercise the Company Matching Option to the extent vested as of Participant’s retirement date, at any time within two (2) years after Participant’s retirement date, but not beyond the original term of the Company Matching Option. To the extent unvested as of the retirement date, the Company Matching Option shall be forfeited. The Committee shall have the authority in its sole discretion to make any interpretations, determinations, and/or take any administrative actions with respect to whether Participant has experienced a Qualified Retirement. |
(ii) | Company Matching RSUs that are unvested as of the Participant’s retirement date are forfeited as of the retirement date. |
(iii) | In the event Participant’s termination of employment qualifies as a Qualified Retirement and Participant also enters into a severance agreement with the Company, the terms of Section III(D) shall apply with respect to the vesting and settlement of the Company Matching RSUs and the Company Matching Option. |
Participant: | Larry J. Merlo |
Employee ID: | XXXXX |
Shares: | 335,697 |
Option Price: | $74.29 |
(i) | 25% of the Option shall vest on the 1st anniversary of the Grant Date; |
(ii) | 25% of the Option shall vest on the 2nd anniversary of the Grant Date; |
(iii) | 25% of the Option shall vest on the 3rd anniversary of the Grant Date; |
(iv) | 25% of the Option shall vest on the 4th anniversary of the Grant Date. |
1. | Pursuant and subject to the provisions of the 2010 Incentive Compensation Plan, as amended (the “ICP”) of CVS Caremark Corporation (the “Company”), on the date set forth above (the “Grant Date”), the Company has awarded and hereby evidences the Restricted Stock Unit (“RSU”) Award to the person named below (the “Participant”), subject to the terms and conditions set forth and incorporated in this Restricted Stock Unit agreement (the “Agreement”). The ICP is hereby made a part hereof and Participant agrees to be bound by all the provisions of the ICP. Capitalized terms not otherwise defined herein shall have the meaning assigned to such term(s) in the ICP. Except as expressly provided below in Sections 4 and 7, upon termination of employment the treatment of RSUs granted pursuant to this Agreement shall be governed under and subject to the terms of the Amended and Restated Employment Agreement between the Company and the Participant dated December 22, 2008, as amended December 21, 2012 (the “Employment Agreement”). On the Grant Date specified above, the Fair Market Value (the “FMV”), which is the Closing Price of the Company’s common stock on the Grant Date, of each RSU equals $74.29. |
Participant: | Larry J. Merlo |
Employee ID: | XXXXX |
RSUs (#): | 53,843 |
2. | Each RSU represents a right to a future payment of one share (“Share”) of Common Stock ($0.01 par value) of the Company, subject to required tax withholding. |
3. | (a) To the extent dividends are paid on Shares while the RSUs remain outstanding and prior to the Settlement Date (as defined below), subject to Section 5(b), Participant shall be entitled to receive a cash payment in an amount equivalent to the cash dividends with respect to the number of Shares covered by the RSUs; provided, however, that no dividends shall be payable with respect to any RSUs forfeited on or prior to the dividend record date. |
4. | Subject to the terms and conditions of the ICP and this Agreement and subject to Participant’s continued employment, Participant shall be entitled to receive (and the Company shall deliver to Participant) the Shares within sixty (60) days following the Vesting Date(s) set forth herein (or in the Employment Agreement, as the case may be), unless delivery of the Shares has been deferred in accordance with Section 5 below (the date of such delivery of the Shares being hereafter referred to as the “Settlement Date”). Each “Vesting Date” , except as otherwise provided in Section 7, shall be in accordance with the schedule set forth below: |
(a) | 50% of the RSUs shall vest on the third anniversary of the Grant Date (“Tranche A”); |
(b) | 50% of the RSUs shall vest on the fifth anniversary of the Grant Date (“Tranche B”); |
(i) | Participant provides at least 12 months’ advance notice to the Committee of his intent to take Approved Early Retirement or Normal Retirement, |
(ii) | Participant fully cooperates with the Company in transitioning his duties during the period between the disclosure to the Committee of his intent to take Approved Early Retirement or Normal Retirement and his retirement date, |
(iii) | Participant continues to be employed by the Company through the Approved Early Retirement or Normal Retirement date, and |
(iv) | the Committee approves such vesting terms (such approval not to be unreasonably withheld), and, in the case of an Approved Early Retirement, approves such retirement. |
5. | (a) In accordance with rules promulgated by the Management Planning and Development Committee of the Board of Directors (the “Committee”), Participant, to the extent eligible under the CVS Caremark Deferred Stock Compensation Plan, may elect to defer delivery of Shares in settlement of RSUs covered by this Agreement. Any such deferred delivery date elected by Participant shall become the Settlement Date for purposes of this Agreement. |
6. | Except as may be elected by Participant, on the Settlement Date the number of Shares to be delivered by the Company to Participant shall be reduced by the smallest number of Shares having a FMV at least equal to the dollar amount of Federal, state and local tax withholding required to be withheld by the Company with respect to such RSUs on such date. In lieu of having the number of Shares underlying the RSU reduced, Participant may elect to pay the Company for any amounts required to be withheld by the Company in connection with the vesting of the RSUs or delivery of the Shares pursuant to the Agreement. Such election may be made electronically at any time prior to the Settlement Date of the RSUs. |
7. | (a) Except as provided in Paragraphs 7(b) – (g) below, if, for any reason other than Approved Early Retirement or Normal Retirement, Participant’s employment with the Company and any subsidiary of the Company terminates, all RSUs not then vested in accordance with Section 4 above shall be treated in accordance with the Employment Agreement. In the event of a conflict between the Employment Agreement and the provisions in Sections 7(b) – (e) of this Agreement, this Agreement shall control. |
(c) | (i) In the event Participant’s employment with the Company and any subsidiary of the Company terminates prior to the third anniversary of the Grant Date, by reason of total and permanent disability (as defined in the Company’s Long-Term Disability Plan, or, if not defined in such Plan, as defined by the Social Security Administration), the RSUs shall vest on a pro rata basis as follows: the total number |
8. | An RSU does not represent an equity interest in the Company and carries no voting rights. Participant shall have no rights of a shareholder with respect to the RSUs until the Shares have been delivered to Participant. |
9. | Neither the execution and delivery hereof nor the granting of the award evidenced hereby shall constitute or be evidence of any agreement or understanding, express or implied, on the part of the Company or its subsidiaries to employ Participant for any specific period. |
1. | Definitions. |
a. | "Base Salary" shall mean Executive's annual rate of base salary at the time of Executive’s termination of employment or, if greater, as in effect immediately prior to a Change in Control. |
b. | "Cause" shall exist if: |
i. | Executive willfully and materially breaches Sections 4 or 5 of this Agreement; |
ii. | Executive is convicted of a felony involving moral turpitude; or |
iii. | Executive engages in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out Executive’s duties under this Agreement, resulting, in either case, in material harm to the financial condition or reputation of the Company. |
c. | A “Change in Control” shall be deemed to have occurred if: |
(i) | any Person (other than (w) the Company, (x) any trustee or other fiduciary holding securities under any employee benefit plan of the Company, (y) any company owned, directly or indirectly, by the stockholders of the Company immediately after the occurrence with respect to which the evaluation is being made in substantially the same proportions as their ownership of the common stock of the Company immediately prior to such occurrence or (z) any surviving or resulting entity from a merger or consolidation referred to in clause (iii) below that does not constitute a Change of Control under clause (iii) below) becomes the Beneficial Owner (except that a Person shall be deemed to be the Beneficial Owner of all shares that any such Person has the right |
(ii) | during any period of twelve (12) consecutive months, individuals who at the beginning of such period constitute the Board, and any new director whose election by the Board or nomination for election by the Company's stockholders was approved by a vote of at least a majority of the directors then still in office who either were directors at the beginning of the twelve (12) month period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the Board; |
(iii) | the consummation of a merger or consolidation of the Company or any Significant Subsidiary with any other entity, other than a merger or consolidation which would result in the voting securities of the Company or a Significant Subsidiary outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or resulting entity) more than 50% of the combined voting power of the surviving or resulting entity outstanding immediately after such merger or consolidation; or |
(iv) | the consummation of a transaction (or series of transactions within a 12 month period) which constitutes the sale or disposition of all or substantially all of the consolidated assets of the Company but in no event assets having a gross fair market value of less than 40% of the total gross fair market value of all of the consolidated assets of the Company (other than such a sale or disposition immediately after which such assets will be owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company immediately prior to such sale or disposition) |
(A) | The term "Beneficial Owner" shall have the meaning ascribed to such term in Rule 13d-3 under the Exchange Act (including any successor to such Rule). |
(B) | The term "Exchange Act" means the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto. |
(C) | The term "Person" shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including "group" as defined in Section 13(d) thereof. |
d. | "Committee" shall mean the Management Planning and Development Committee of the Board, or the corresponding committee of the board of directors of a successor to CVS Caremark. |
e. | "Company" shall mean, collectively, CVS Caremark and any Subsidiary or affiliate of CVS Caremark. |
f. | "Confidential Information" shall have the meaning set forth in Section 4 below. |
g. | "Constructive Termination Without Cause" shall mean a termination of the Executive's employment at Executive’s initiative following the occurrence, without the Executive's written consent, of one or more of the following events (except as a result of a prior termination): |
i. | an assignment of any duties to Executive that is inconsistent with Executive’s status as a member of the senior management of CVS Caremark; |
ii. | a decrease in Executive's annual base salary or target annual incentive award opportunity; |
iii. | any failure to secure the agreement of any successor to CVS Caremark to fully assume the Company’s obligations under this Agreement; or |
iv. | a relocation of Executive's principal place of employment more than 35 miles from Executive’s place of employment before such relocation. |
h. | "Disability" shall mean disability as that term is defined in the Company's Long-Term Disability Plan. |
i. | "Effective Date" shall have the meaning set forth in Section 2 below. |
j. | "Original Term" shall have the meaning set forth in Section 2 below. |
k. | "Renewal Term" shall have the meaning set forth in Section 2 below. |
l. | "Severance Period" shall mean the period of 18 months following the termination of Executive's employment with the Company. |
m. | "Subsidiary" shall have the meaning set forth in Section 4 below. |
n. | "Term" shall have the meaning set forth in Section 2 below. |
o. | “termination of employment”, “employment is terminated” and other similar words shall mean with respect to Executive |
(A) | except in the case where Executive is on a bona fide leave of absence pursuant to the Company’s policies as provided below, Executive is deemed to have incurred a Separation from Service on a date if the company and Executive reasonably anticipate that the level of services to be performed by Executive after such date would be permanently reduced to 20% or less of the average services rendered by Executive during the immediately preceding 36-month period (or the total period of employment, if less than |
(B) | if Executive is absent from work due to military leave, sick leave, or other bona fide leave of absence pursuant to the Company’s policies, Executive shall incur a Separation from Service on the first date that the rules of (A), above, are satisfied following the later of (i) the six-month anniversary of the commencement of the leave or (ii) the expiration of Executive’s right, if any, to reemployment under statute, contract or Company policy; |
(C) | Executive shall be considered to continue employment and to not have a Separation from Service while on a bona fide leave of absence pursuant to the Company’s policies if the leave does not exceed 6 consecutive months (12) months for a disability leave of absence) or, if longer, so long as the Executive retains a right to reemployment with the Company or an Affiliate under an applicable statute, contract or Company policy. For this purpose, a “disability leave of absence” is an absence due to any medically determinable physical or mental impairment of Executive that can be expected to result in death or can be expected to last for a continuous period of not less than 6 months, where such impairment causes the Participant to be unable to perform the duties of his job or a substantially similar job; |
(D) | for purposes of determining whether another organization is an Affiliate of the Company, common ownership of at least 50% shall be determinative; |
(E) | the Company specifically reserves the right to determine whether a sale or other disposition of substantial assets to an unrelated party constitutes a Separation from Service with respect to Executive providing services to the seller immediately prior to the transaction and providing services to the buyer after the transaction. Such determination shall be made in accordance with the requirements of Section 409A of the Code; or |
(ii) | for any plan or arrangement that is not subject to the rules of Section 409A of the Code, the complete cessation of providing service to the Company or any Affiliate as an employee. |
2. | Term of Agreement. |
3. | Entitlement to Severance Benefit. |
a. | Severance Benefit. In the event Executive's employment with the Company is Terminated Without Cause, other than due to death, or Disability, or in the event there is a Constructive Termination Without Cause within two years following a Change in Control, Executive shall be entitled to receive: |
i. | Base Salary through the date of termination of Executive's employment, which shall be paid in a cash lump sum not later than 15 days following Executive's termination of employment; |
ii. | An amount equal to 1.5 times Executive's Base Salary in effect on the date of termination of Executive's employment (or in the event a reduction in Base Salary is a basis for a Constructive Termination Without Cause, then the Base Salary in effect immediately prior to such reduction), payable in a cash lump sum following Executive's termination of employment; |
iii. | An amount equal to the most recently established target annual cash incentive bonus amount, pro rated based on the portion of the performance year that Executive has worked as of the date of Executive’s termination. The Base Salary will be determined in accordance with Section 3.a.ii. Such payment of a pro rata annual cash incentive bonus and cash in lieu of Performance-Based Restricted Stock will be payable in a cash lump sum following Executive's termination of employment; |
iv. | An amount equal to 1.5 times the most recently established target annual incentive cash bonus amount, payable in a cash lump sum following the Executive's termination of employment; |
v. | Elimination of all restrictions on any restricted stock or restricted .stock unit awards outstanding at the time of termination of employment (other than awards under the Company's Partnership Equity Program, which shall be governed by the terms of such awards); |
vi. | Immediate vesting of all outstanding stock options and the right to exercise such stock options for the remainder of the full term of such option (other than awards under the Company's Partnership Equity Program, which shall be governed by the terms of such awards); |
vii. | The balance of any incentive awards earned as of December 31 of the prior year (but not yet paid), which shall be paid in a single lump sum not later than 15 days following Executive's termination of employment; |
viii. | Settlement of all deferred compensation arrangements in accordance with any then applicable deferred compensation plan or election form; |
ix. | Continued participation in all medical, health and life insurance plans at the same benefit level at which Executive was participating on the date of termination of Executive’s employment until the earlier of: |
1. | the end of the Severance Period; or |
2. | the date, or dates, Executive receives equivalent coverage and benefits under the plans and programs of a subsequent employer (such coverage and benefits to be determined on a coverage-by-coverage, or benefit-by-benefit, basis); |
x. | other or additional benefits then due or earned in accordance with applicable plans and programs of the Company. |
b. | Excise Tax Gross-Up. If while a member of the Business Planning Committee of the Company Executive becomes entitled to one or more payments (with a "payment" including, without limitation, the vesting of an option or other non-cash benefit or property), whether pursuant to the terms of this Agreement or any other plan, arrangement, or agreement with the Company or any affiliated company (the "Total Payments"), which are or become subject to the tax imposed by Code Section 4999 (or any similar tax that may hereafter be imposed) (the "Excise Tax"), the Company shall pay to Executive at the time specified below an additional amount (the "Gross-up Payment") (which shall include, without limitation, reimbursement for any penalties and interest that may accrue in respect of such Excise Tax) such that the net amount retained by the Executive, after reduction for any Excise Tax (including any penalties or interest thereon) on the Total Payments and any federal, state and local income or employment tax and Excise Tax on the Gross-up Payment provided for by this Section 3.b., but before reduction for any federal, state, or local income or employment tax on the Total Payments, shall be equal to the sum of (a) the Total Payments, and (b) an amount equal to the product of any deductions disallowed for federal, state, or local income tax purposes because of the inclusion of the Gross-up Payment in Executive's adjusted gross income multiplied by the highest applicable marginal rate of federal, state, or local income taxation, respectively, for the calendar year in which the Gross-up Payment is to be made. For purposes of determining whether any of the Total Payments will be subject to the Excise Tax and the amount of such Excise Tax: |
(i) | The Total Payments shall be treated as "parachute payments" within the meaning of Code Section 280G(b)(2), and all "excess parachute payments" within the meaning of Code Section 280G(b)(1) shall be treated as subject to the Excise Tax, unless, and except to the extent that, in the written opinion of independent compensation consultants, counsel or auditors of nationally recognized standing ("Independent Advisors") selected by the Company and reasonably acceptable to the Executive, the Total Payments (in whole or in part) do not constitute parachute payments, or such excess parachute payments (in whole or in part) represent reasonable compensation for services actually rendered within the meaning of Code Section 280G(b)(4) in excess of the base amount within the meaning of Code Section 280G(b)(3) or are otherwise not subject to the Excise Tax; |
(ii) | The amount of the Total Payments which shall be treated as subject to the Excise Tax shall be equal to the lesser of (A) the total amount of the Total Payments or (B) the total amount of excess parachute payments within the meaning of Code Section 280G(b)(1) (after applying clause (i) above); and |
(iii) | The value of any non-cash benefits or any deferred payment or benefit shall be determined by the Independent Advisors in accordance with the principles of Code Sections 280G(d)(3) and (4). |
c. | No Mitigation; No Offset. In the event of any termination of employment under this Section 3, Executive shall be under no obligation to seek other employment, and the |
d. | Nature of Payments. Any amounts due under this Section 3 are in the nature of severance payments considered to be reasonable by the Company and are not in the nature of a penalty. |
e. | Exclusivity of Severance Benefit. Upon termination of Executive's employment during the Term, Executive shall not be entitled to any severance payments or severance benefits from the Company, or any other payments by the Company, other than the Severance Benefit provided in this Section 3, except as required by law. |
f. | General Release of Claims. Executive agrees, as a condition of payment of the Severance Benefit provided for in this Section 3, that Executive will execute within 60 days of Executive’s termination of employment a separation agreement, in a form reasonably satisfactory to the Company, that includes a general release of any and all claims arising out of Executive's employment or termination of employment with the Company, other than claims for (i) enforcement of this Agreement, (ii) enforcement of Executive's rights under any of the Company's incentive compensation, equity and/or employee benefit plans and programs to which Executive is entitled under this Agreement, and (iii) any tort for personal injury not arising out of or related to Executive’s employment or termination of employment. |
g. | Subject to the provisions of Section 13(b), all payments to be made pursuant to this Section 3 upon the termination of employment of Executive shall be made or commence, as the case may be, within 75 days after the Executive’s termination of employment provided, however, that if such termination of employment is after October 17 of a year, the payout or first payment, as the case may be, shall be made at the end of such 75 day period. |
4. | Confidentiality; Cooperation with Regard to Litigation; Non-disparagement. |
a. | During the Term and thereafter, Executive shall not, without the prior written consent of the Company, disclose to anyone (except in good faith in the ordinary course of business to a person who will be advised by Executive to keep such information confidential) or make use of any confidential information except in the performance of Executive’s duties hereunder or when required to do so by legal process, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) that requires Executive to divulge, disclose or make accessible such information. In the event that Executive is so ordered, Executive shall give prompt written notice to the Company in order to allow the Company the opportunity to object to or otherwise resist such order. |
b. | During the Term and thereafter, Executive shall not disclose the existence or contents of this Agreement beyond what is disclosed in the proxy statement or documents filed with the government unless and to the extent such disclosure is required by law, by a governmental agency, or in a document required by law to be filed with a governmental agency or in connection with enforcement of his/her rights under this Agreement. In the event that disclosure is so required, Executive shall give prompt written notice to the Company in order to allow the Company the opportunity to object to or otherwise resist such requirement. This restriction shall not apply to such disclosure by Executive to members of his/her immediate family, his/her tax, legal or financial advisors, any lender, or tax authorities, or to potential future employers to the extent necessary, each of whom shall be advised not to disclose such information. |
c. | “Confidential Information" shall mean all information concerning the business of the Company or any Subsidiary relating to any of their products, product development, trade secrets, customers, suppliers, finances, and business plans and strategies. Excluded from the definition of Confidential Information is information (i) that is or becomes part of the public domain, other than through the breach of this Agreement by Executive or (ii) regarding the Company's business or industry properly acquired by Executive in the course of Executive’s career as an Executive in the Company's industry and independent of Executive's employment by the Company. For this purpose, information known or available generally within the trade or industry of the Company or any Subsidiary shall be deemed to be known or available to the public. |
d. | "Subsidiary" shall mean any corporation or other business entity owned or controlled directly or indirectly by CVS Caremark. |
e. | Executive agrees to cooperate with the Company, during the Term and thereafter (including following Executive's termination of employment for any reason), by being reasonably available to testify on behalf of the Company or any Subsidiary in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, and to assist the Company, or any Subsidiary, in any such action, suit, or proceeding, by providing information and meeting and consulting with the Board or its representatives or counsel, or representatives or counsel to the Company, or any Subsidiary as requested; provided, however that the same does not materially interfere with Executive’s then current professional activities. The Company agrees to reimburse Executive on an after tax basis, for all reasonable expenses actually incurred in connection with Executive’s provision of testimony or assistance. |
f. | Executive agrees that, during the Term and thereafter (including following Executive's termination of employment for any reason) Executive will not make statements or representations, or otherwise communicate, directly or indirectly, in writing, orally, or otherwise, or take any action which may, directly or indirectly, disparage or be damaging to the Company or any Subsidiary or their respective officers, directors, employees, advisors, businesses or reputations. Notwithstanding the foregoing, nothing in this Agreement shall preclude Executive from making truthful statements or disclosures that are required by applicable law, regulation or legal process. |
5. | Non-solicitation. |
6. | Remedies. |
7. | Effect of Agreement on Other Benefits. |
8. | Not an Employment Agreement. |
9. | Resolution of Disputes. |
10. | Assignability; Binding Nature. |
11. | Representation. |
12. | Entire Agreement. |
13. | Amendment or Waiver, Section 409A. |
(a) | No provision in this Agreement may be amended unless such amendment is agreed to in writing and signed by Executive and an authorized officer of the Company. No waiver by either Party of any breach by the other Party of any condition or provision contained in this Agreement to be performed by such other Party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by Executive or an authorized officer of the Company, as the case may be. |
(b) | Executive and Company agree that it is the intent of the parties that this Agreement not violate any applicable provision of, or result in any additional tax or penalty under, Section 409A of the Code, as amended, and that to the extent any provisions of this Agreement do not comply with such Code Section 409A the parties will make such changes as are mutually agreed upon in order to comply with Code Section 409A. In all events, to the extent required to avoid a violation of the applicable rules under all Section 409A by reason of Code Section 409A(a)(2)(B)(i), payment of any amounts subject to Code Section 409A shall be delayed until the relevant date of payment that will result in compliance with the rules of Code Section 409A(a)(2)(B)(i). |
14. | Severability. |
15. | Survivorship. |
16. | Beneficiaries/References. |
17. | Governing Law/Jurisdiction. |
18. | Notices. |
19. | Headings. |
20. | Counterparts. |
CVS Pharmacy, Inc. | |
By: | /s/ V. Michael Ferdinandi |
Name: V. Michael Ferdinandi | |
Title: Senior Vice President Human Resources, Corporate Communications and Community Relations |
Executive |
/s/ Helena Foulkes |
Helena Foulkes |
Senior Vice President, Health Care Services |
1. | The definition of “Constructive Termination Without Cause” in Section 1.g. of the Agreement shall be revised to read as follows: |
i. | an assignment of any duties to Executive that is materially inconsistent with Executive’s status as a member of the senior management of CVS Caremark; |
ii. | a material decrease in Executive’s annual base salary or target annual incentive award opportunity; |
iii. | the failure to secure the agreement of any successor to CVS Caremark to fully assume the Company’s material obligations under this Agreement; or |
iv. | a relocation of Executive’s principal place of employment more than 35 miles from Executive’s principal place of employment before such relocation. |
2. | Section 3.b., Excise Tax Gross-Up, of the Agreement shall be deleted in its entirety and replaced with the following new Section 3.b.: |
3. | All other terms and conditions of the Agreement shall remain unchanged and in effect. |
CVS Pharmacy, Inc. | |
By: | /s/ Lisa G. Bisaccia |
Name: Lisa G. Bisaccia | |
Title: Senior Vice President and Chief Human Resource Officer | |
Executive | |
/s/: Helena B. Foulkes | |
Name: Helena Foulkes | |
Title: Exective Vice President and Chief Health Care Strategy and Marketing Officer |
Year Ended December 31, | |||||||||||
In millions, except per common share amounts | 2014 | 2013 | 2012 | ||||||||
Net revenues | $ | 139,367 | $ | 126,761 | $ | 123,120 | |||||
Cost of revenues | 114,000 | 102,978 | 100,632 | ||||||||
Gross profit | 25,367 | 23,783 | 22,488 | ||||||||
Operating expenses | 16,568 | 15,746 | 15,278 | ||||||||
Operating profit | 8,799 | 8,037 | 7,210 | ||||||||
Interest expense, net | 600 | 509 | 557 | ||||||||
Loss on early extinguishment of debt | 521 | — | 348 | ||||||||
Income before income tax provision | 7,678 | 7,528 | 6,305 | ||||||||
Income tax provision | 3,033 | 2,928 | 2,436 | ||||||||
Income from continuing operations | 4,645 | 4,600 | 3,869 | ||||||||
Loss from discontinued operations, net of tax | (1 | ) | (8 | ) | (7 | ) | |||||
Net income | 4,644 | 4,592 | 3,862 | ||||||||
Net loss attributable to noncontrolling interest | — | — | 2 | ||||||||
Net income attributable to CVS Health | $ | 4,644 | $ | 4,592 | $ | 3,864 | |||||
Diluted earnings per common share: | |||||||||||
Income from continuing operations attributable to CVS Health | $ | 3.96 | $ | 3.75 | $ | 3.02 | |||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | (0.01 | ) | $ | (0.01 | ) | |||
Net income attributable to CVS Health | $ | 3.96 | $ | 3.74 | $ | 3.02 |
• | During 2014, net revenues in our Pharmacy Services Segment increased 16.1% and net revenues in our Retail Pharmacy Segment increased 3.3% compared to the prior year. |
• | During 2013, net revenues in our Pharmacy Services Segment increased by 3.8% and net revenues in our Retail Pharmacy Segment increased 3.1% compared to the prior year. |
• | The increase in our generic dispensing rates in both of our operating segments continued to have an adverse effect on net revenue in 2014 as compared to 2013, as well as in 2013 as compared to 2012. In 2014, the Pharmacy Services Segment had a greater impact from net new business as compared to 2013. |
• | During 2014, gross profit in our Pharmacy Services Segment and Retail Pharmacy Segment increased by 12.6% and 5.8%, respectively, compared to the prior year. For the year ended December 31, 2014, gross profit as a percent of net revenues in our Pharmacy Services Segment and Retail Pharmacy Segment was 5.4% and 31.4%, respectively. |
• | During 2013, gross profit in our Pharmacy Services Segment and Retail Pharmacy Segment increased by 11.3% and 5.3%, respectively, compared to the prior year. For the year ended December 31, 2013, gross profit as a percent of net revenues in our Pharmacy Services Segment and Retail Pharmacy Segment was 5.6% and 30.6%, respectively. |
• | The increased weighting toward the Pharmacy Services Segment, which has a lower gross profit than the Retail Pharmacy Segment, resulted in a decline in consolidated gross profit as a percent of net revenues in 2014 as compared |
• | Our gross profit continued to benefit from the increased utilization of generic drugs (which normally yield a higher gross profit rate than equivalent brand name drugs) in both the Pharmacy Services and Retail Pharmacy segments for 2012 through 2014, offsetting the negative impacts described above. |
In millions | 2014 | 2013 | 2012 | ||||||||
Interest expense | $ | 615 | $ | 517 | $ | 561 | |||||
Interest income | (15 | ) | (8 | ) | (4 | ) | |||||
Interest expense, net | $ | 600 | $ | 509 | $ | 557 |
In millions | Pharmacy Services Segment(1)(2) | Retail Pharmacy Segment(2) | Corporate Segment | Intersegment Eliminations(2) | Consolidated Totals | ||||||||||||||
2014: | |||||||||||||||||||
Net revenues | $ | 88,440 | $ | 67,798 | $ | — | $ | (16,871 | ) | $ | 139,367 | ||||||||
Gross profit | 4,771 | 21,277 | — | (681 | ) | 25,367 | |||||||||||||
Operating profit (loss) | 3,514 | 6,762 | (796 | ) | (681 | ) | 8,799 | ||||||||||||
2013: | |||||||||||||||||||
Net revenues | $ | 76,208 | $ | 65,618 | $ | — | $ | (15,065 | ) | $ | 126,761 | ||||||||
Gross profit | 4,237 | 20,112 | — | (566 | ) | 23,783 | |||||||||||||
Operating profit (loss) | 3,086 | 6,268 | (751 | ) | (566 | ) | 8,037 | ||||||||||||
2012: | |||||||||||||||||||
Net revenues | $ | 73,444 | $ | 63,641 | $ | — | $ | (13,965 | ) | $ | 123,120 | ||||||||
Gross profit | 3,808 | 19,091 | — | (411 | ) | 22,488 | |||||||||||||
Operating profit (loss) | 2,679 | 5,636 | (694 | ) | (411 | ) | 7,210 |
(1) | Net revenues of the Pharmacy Services Segment include approximately $8.1 billion, $7.9 billion and $8.4 billion of Retail Co-Payments for 2014, 2013 and 2012, respectively. See Note 1 to the consolidated financial statements for additional information about Retail Co-Payments. |
(2) | Intersegment eliminations relate to two types of transactions: (i) Intersegment revenues that occur when Pharmacy Services Segment customers use Retail Pharmacy Segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis, and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services Segment customers, through the Company’s intersegment activities (such as the Maintenance Choice® program), elect to pick-up their maintenance prescriptions at Retail Pharmacy Segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. The following amounts are eliminated in consolidation in connection with the item (ii) intersegment activity: net revenues of $4.9 billion, $4.3 billion and $3.4 billion for the years ended December 31, 2014, 2013 and 2012, respectively; and gross profit and operating profit of $681 million, $566 million and $411 million for the years ended December 31, 2014, 2013 and 2012, respectively. |
Year Ended December 31, | |||||||||||
In millions | 2014 | 2013 | 2012 | ||||||||
Net revenues | $ | 88,440 | $ | 76,208 | $ | 73,444 | |||||
Gross profit | $ | 4,771 | $ | 4,237 | $ | 3,808 | |||||
Gross profit % of net revenues | 5.4 | % | 5.6 | % | 5.2 | % | |||||
Operating expenses | $ | 1,257 | $ | 1,151 | $ | 1,129 | |||||
Operating expenses % of net revenues | 1.4 | % | 1.5 | % | 1.5 | % | |||||
Operating profit | $ | 3,514 | $ | 3,086 | $ | 2,679 | |||||
Operating profit % of net revenues | 4.0 | % | 4.1 | % | 3.6 | % | |||||
Net revenues(1) : | |||||||||||
Mail choice(2) | $ | 31,081 | $ | 24,791 | $ | 22,843 | |||||
Pharmacy network(3) | $ | 57,122 | $ | 51,211 | $ | 50,411 | |||||
Other | $ | 237 | $ | 206 | $ | 190 | |||||
Pharmacy claims processed(1) : | |||||||||||
Total | 932.0 | 902.1 | 880.5 | ||||||||
Mail choice(2) | 82.4 | 83.3 | 81.7 | ||||||||
Pharmacy network(3) | 849.6 | 818.8 | 798.8 | ||||||||
Generic dispensing rate(1) : | |||||||||||
Total | 82.2 | % | 80.5 | % | 78.2 | % | |||||
Mail choice(2) | 74.6 | % | 72.6 | % | 68.9 | % | |||||
Pharmacy network(3) | 83.0 | % | 81.3 | % | 79.1 | % | |||||
Mail choice penetration rate | 21.4 | % | 22.6 | % | 22.7 | % |
(1) | Pharmacy network net revenues, claims processed and generic dispensing rates do not include Maintenance Choice, which are included within the mail choice category. |
(2) | Mail choice is defined as claims filled at a Pharmacy Services mail facility, which includes specialty mail claims, as well as 90-day claims filled at our retail stores under the Maintenance Choice program. |
(3) | Pharmacy network is defined as claims filled at retail pharmacies, including our retail drugstores, but excluding Maintenance Choice activity. |
• | Our mail choice claims processed decreased 1.1% to 82.4 million claims in the year ended December 31, 2014, compared to 83.3 million claims in the prior year. The decrease in mail choice claims was driven by a decline in traditional mail volumes, which was mostly offset by growth in our Maintenance Choice program and specialty pharmacy. During 2013, our mail choice claims processed increased 1.9% to 83.3 million claims. The increase in mail choice claim volume was primarily due to specialty claim volume and increased claims associated with the continuing client adoption of our Maintenance Choice offerings. |
• | During 2014 and 2013, our average revenue per mail choice claim increased by 26.8% and 6.5%, compared to 2013 and 2012, respectively. This increase in 2014 was primarily due to the acquisition of Coram and drug inflation particularly in |
• | Our mail choice generic dispensing rate was 74.6%, 72.6% and 68.9% in the years ended December 31, 2014, 2013 and 2012, respectively. Our pharmacy network generic dispensing rate increased to 83.0% in the year ended December 31, 2014, compared to 81.3% in the prior year. During 2013, our pharmacy network generic dispensing rate increased to 81.3% compared to our pharmacy network generic dispensing rate of 79.1% in 2012. These continued increases in mail choice and pharmacy network generic dispensing rates were primarily due to the impact of new generic drug introductions, primarily in 2012, and our continuous efforts to encourage plan members to use generic drugs when they are available. We believe our generic dispensing rates will continue to increase in future periods, albeit, at a slower pace. This increase will be affected by, among other things, the number of new generic drug introductions and our success at encouraging plan members to utilize generic drugs when they are available and clinically appropriate. |
• | Our pharmacy network claims processed increased 3.8% to 849.6 million claims in the year ended December 31, 2014, compared to 818.8 million claims in the prior year. This increase was primarily due to net new business and growth in Managed Medicaid, partially offset by a decrease in Medicare Part D claims. Medicare Part D claims were negatively impacted by the CMS sanctions that were in place during 2013. See “Regulatory and business changes relating to our participation in Medicare Part D” in Part I, Item 1A, Risk Factors within our Form 10-K for the year ended December 31, 2014 (“2014 Form 10-K”), for additional information. During 2013, our pharmacy network claims processed increased 2.5% to 818.8 million compared to 798.8 million pharmacy network claims processed in 2012. This increase was primarily due to higher claims activity associated with our Medicare Part D offering. |
• | Our average revenue per pharmacy network claim processed increased 7.5% in the year ended December 31, 2014 as compared to the prior year. This increase was primarily due to drug inflation and changes in the drug mix, partially offset by increases in the generic dispensing rate. During 2013, our average revenue per pharmacy network claim processed decreased by 0.9%, compared to 2012. This decrease was primarily due to increases in the generic dispensing rate. |
• | We completed the roll out of Specialty ConnectTM in May 2014, which integrates the Company’s specialty pharmacy mail and retail capabilities, providing members with the choice to bring their specialty prescriptions to any CVS/pharmacy® location. Whether submitted through our mail order pharmacy or at CVS/pharmacy, all prescriptions are filled through the Company’s specialty mail order pharmacies, so all revenue from this specialty prescription services program is recorded within the Pharmacy Services Segment. |
• | The Pharmacy Services Segment recognizes revenues for its pharmacy network transactions based on individual contract terms. Our Pharmacy Services Segment contracts are predominantly accounted for using the gross method. See the “Revenue Recognition” description under “Critical Accounting Policies” later in this section for further information on our revenue recognition policy. |
• | Our gross profit dollars and gross profit as a percentage of net revenues continued to be impacted by our efforts to (i) retain existing clients, (ii) obtain new business and (iii) maintain or improve the rebates and/or discounts we received from manufacturers, wholesalers and retail pharmacies. In particular, competitive pressures in the PBM industry have caused us and other PBMs to continue to share a larger portion of rebates and/or discounts received from pharmaceutical manufacturers with clients. In addition, market dynamics and regulatory changes have impacted our ability to offer plan sponsors pricing that includes retail network “differential” or “spread”. We expect these trends to continue. The “differential” or “spread” is any difference between the drug price charged to plan sponsors, including Medicare Part D plan sponsors, by a PBM and the price paid for the drug by the PBM to the dispensing provider. The increased use of generic drugs has positively impacted our gross profit margins but has resulted in third party payors augmenting their efforts to reduce reimbursement payments for prescriptions. This trend, which we expect to continue, reduces the benefit we realize from brand to generic product conversions. |
• | We review our network contracts on an individual basis to determine if the related revenues should be accounted for using the gross method or net method under the applicable accounting rules. Our Pharmacy Services Segment network contracts are predominantly accounted for using the gross method, which results in higher revenues, higher cost of revenues and lower gross profit rates. |
• | Our gross profit as a percentage of revenues benefited from the increase in our total generic dispensing rate, which increased to 82.2% and 80.5% in 2014 and 2013, respectively, compared to our generic dispensing rate of 78.2% in 2012. These increases were primarily due to new generic drug introductions and our continued efforts to encourage plan members to use generic drugs when they are available. We expect these trends to continue, albeit at a slower pace. |
• | Operating expenses increased $106 million or 9.2%, to $1.3 billion, in the year ended December 31, 2014, compared to the prior year. The increase in operating expenses is primarily related to increased costs associated with infusion services due to the 2014 acquisition of Coram, as well as an $11 million gain from a legal settlement during the year ended December 31, 2013. The slight decrease in operating expenses as a percentage of net revenues was primarily due to expense leverage from net revenue growth. |
• | During 2013, the increase in operating expenses of $22 million or 1.9%, to $1.2 billion compared to 2012, is primarily related to costs associated with the remediation of Medicare Part D sanctions and coverage determination issues discussed below. Operating expenses as a percentage of net revenues remained relatively flat. |
Year Ended December 31, | |||||||||||
In millions | 2014 | 2013 | 2012 | ||||||||
Net revenues | $ | 67,798 | $ | 65,618 | $ | 63,641 | |||||
Gross profit | $ | 21,277 | $ | 20,112 | $ | 19,091 | |||||
Gross profit % of net revenues | 31.4 | % | 30.6 | % | 30.0 | % | |||||
Operating expenses | $ | 14,515 | $ | 13,844 | $ | 13,455 | |||||
Operating expenses % of net revenues | 21.4 | % | 21.1 | % | 21.1 | % | |||||
Operating profit | $ | 6,762 | $ | 6,268 | $ | 5,636 | |||||
Operating profit % of net revenues | 10.0 | % | 9.6 | % | 8.9 | % | |||||
Retail prescriptions filled (90 Day = 3 prescriptions) (1) | 935.9 | 890.1 | 845.8 | ||||||||
Net revenue increase (decrease): | |||||||||||
Total | 3.3 | % | 3.1 | % | 6.8 | % | |||||
Pharmacy | 5.1 | % | 4.1 | % | 7.6 | % | |||||
Front Store | (2.5 | )% | 1.0 | % | 5.1 | % | |||||
Total prescription volume (90 Day = 3 prescriptions) (1) | 5.2 | % | 5.2 | % | 11.0 | % | |||||
Same store sales increase (decrease): | |||||||||||
Total | 2.1 | % | 1.7 | % | 5.6 | % | |||||
Pharmacy | 4.8 | % | 2.6 | % | 6.6 | % | |||||
Front Store | (4.0 | )% | (0.5 | )% | 3.4 | % | |||||
Prescription volume (90 Day = 3 prescriptions) (1) | 4.1 | % | 4.4 | % | 10.0 | % | |||||
Generic dispensing rates | 83.1 | % | 81.4 | % | 79.2 | % | |||||
Pharmacy % of net revenues | 70.7 | % | 69.5 | % | 68.8 | % | |||||
Third party % of pharmacy revenue | 98.6 | % | 97.9 | % | 97.5 | % |
(1) | Includes the adjustment to convert 90-day, non-specialty prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription. |
• | Front store same store sales declined 4.0% in the year ended December 31, 2014, as compared to the prior year. The decrease is primarily due to the Company’s decision to stop selling tobacco products, softer customer traffic and a less severe flu season than the prior year and extreme weather conditions across much of the United States during the first quarter of 2014. The decrease was partially offset by an increase in basket size. Front store same store sales would have been approximately 350 basis points higher for the year ended December 31, 2014 if tobacco and the estimated associated basket sales were excluded from both the years ended December 31, 2014 and 2013. |
• | Pharmacy same store sales rose 4.8% in the year ended December 31, 2014, as compared to the prior year. Pharmacy same store sales were positively impacted by same store script growth of 4.1%, partially offset by the impact of the increase in generic dispensing and reimbursement pressure. Pharmacy same store sales for the year ended December 31, 2014 were negatively impacted by approximately 140 basis points from the implementation of Specialty Connect. Specialty Connect transitioned all specialty prescriptions to the Pharmacy Services Segment, as they are being processed through the |
• | Pharmacy revenues continue to be negatively impacted by the conversion of brand name drugs to equivalent generic drugs, which typically have a lower selling price. Pharmacy same store sales were negatively impacted by approximately 160 and 540 basis points for the years ended December 31, 2014 and 2013, respectively, due to recent generic introductions. The decrease in the impact from 2013 to 2014 was primarily due to a smaller impact from new generic drug introductions. In addition, our pharmacy revenue growth has also been affected by continued reimbursement pressure, the lack of significant new brand name drug introductions, as well as an increase in the number of over-the-counter remedies that were historically only available by prescription. |
• | As of December 31, 2014, we operated 7,822 retail stores compared to 7,660 retail stores as of December 31, 2013 and 7,458 retail stores as of December 31, 2012. Total net revenues from new stores contributed approximately 1.1%, 1.0% and 1.1% to our total net revenue percentage increase in 2014, 2013, and 2012, respectively. |
• | Pharmacy revenue growth continued to benefit from increased utilization by Medicare Part D beneficiaries, our ability to attract and retain managed care customers and favorable industry trends. These trends include an aging American population; many “baby boomers” are now in their fifties and sixties and are consuming a greater number of prescription drugs, as well as expanded coverage from the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act (collectively, “ACA”). In addition, the increased use of pharmaceuticals as the first line of defense for individual health care also contributed to the growing demand for pharmacy services. We believe these favorable industry trends will continue. |
• | Gross profit dollars and margin for the year ended December 31, 2014 were positively impacted by $53 million related to the favorable resolution of previously proposed retroactive reimbursement rate changes in the State of California’s Medicaid program. |
• | Sales to customers covered by third party insurance programs are a large component of our total pharmacy business. On average, our gross profit on third party pharmacy revenues is lower than our gross profit on cash pharmacy revenues. Third party pharmacy revenues were 98.6% of pharmacy revenues in 2014, compared to 97.9% and 97.5% of pharmacy revenues in 2013 and 2012, respectively. |
• | Front store revenues as a percentage of total net revenues for the years ended December 31, 2014, 2013 and 2012 were 28.8%, 30.5% and 31.2%, respectively. The decline in front store revenues as a percentage of total net revenues in 2014 was largely due to the removal of tobacco products and the estimated associated basket sales. On average, our gross profit on front store revenues is generally higher than our gross profit on pharmacy revenues. Pharmacy revenues as a percentage of total net revenues increased approximately 120, 60 and 50 basis points in the years ended December 31, 2014, 2013 and |
• | During the year ended December 31, 2014, our front store gross profit as a percentage of net revenues increased compared to the prior year. The increase is primarily related to a change in the mix of products sold, including the removal of tobacco products from our stores, and higher store brand sales. |
• | Our pharmacy gross profit rates have been adversely affected by the efforts of managed care organizations, pharmacy benefit managers and governmental and other third party payors to reduce their prescription drug costs. In the event this trend continues, we may not be able to sustain our current rate of revenue growth and gross profit dollars could be adversely impacted. The increased use of generic drugs has positively impacted our gross profit margins but has resulted in third party payors augmenting their efforts to reduce reimbursement payments to retail pharmacies for prescriptions. This trend, which we expect to continue, reduces the benefit we realize from brand to generic product conversions. |
• | ACA made several significant changes to Medicaid rebates and to reimbursement. One of these changes was the proposed revision of the definition of Average Manufacturer Price (“AMP”) and the reimbursement formula for multi-source drugs. Changes in reporting of AMP or other adjustments that may be made regarding the reimbursement of drug payments by Medicaid and Medicare could impact our pricing to customers and other payors and/or could impact our ability to negotiate discounts or rebates with manufacturers, wholesalers, PBMs or retail and mail pharmacies. See “Efforts to reduce reimbursement levels and alter health care financing practices” in Part I, Item 1A, Risk Factors within our 2014 Form 10-K, for additional information. |
Year Ended December 31, | ||||||||||||
in millions | 2014 | 2013 | 2012 | |||||||||
Net cash provided by operating activities | $ | 8,137 | $ | 5,783 | $ | 6,671 | ||||||
Net cash used in investing activities | (4,045 | ) | (1,835 | ) | (1,849 | ) | ||||||
Net cash used in financing activities | (5,694 | ) | (1,237 | ) | (4,860 | ) | ||||||
Effect of exchange rate changes on cash and cash equivalents | (6 | ) | 3 | — | ||||||||
Net increase (decrease) in cash and cash equivalents | $ | (1,608 | ) | $ | 2,714 | $ | (38 | ) |
2014(2) | 2013(2) | 2012(2) | ||||||
Total stores (beginning of year) | 7,702 | 7,508 | 7,388 | |||||
New and acquired stores(1) | 187 | 213 | 150 | |||||
Closed stores(1) | (23 | ) | (19 | ) | (30 | ) | ||
Total stores (end of year) | 7,866 | 7,702 | 7,508 | |||||
Relocated stores | 60 | 78 | 90 |
Authorization Date | Amount of Authorization | ||
In billions | |||
December 15, 2014 (“2014 Repurchase Program”) | $ | 10.0 | |
December 17, 2013 (“2013 Repurchase Program”) | $ | 6.0 | |
September 19, 2012 (“2012 Repurchase Program”) | $ | 6.0 | |
August 23, 2011 (“2011 Repurchase Program”) | $ | 4.0 |
Payments Due by Period | |||||||||||||||||||
In millions | Total | 2015 | 2016 to 2017 | 2018 to 2019 | Thereafter | ||||||||||||||
Operating leases | $ | 27,282 | $ | 2,279 | $ | 4,341 | $ | 3,868 | $ | 16,794 | |||||||||
Lease obligations from discontinued operations | 51 | 16 | 24 | 6 | 5 | ||||||||||||||
Capital lease obligations | 810 | 47 | 94 | 96 | 573 | ||||||||||||||
Long-term debt | 11,879 | 563 | 2,276 | 2,494 | 6,546 | ||||||||||||||
Interest payments on long-term debt(1) | 5,173 | 484 | 867 | 689 | 3,133 | ||||||||||||||
Other long-term liabilities reflected in our consolidated balance sheet | 652 | 48 | 254 | 100 | 250 | ||||||||||||||
$ | 45,847 | $ | 3,437 | $ | 7,856 | $ | 7,253 | $ | 27,301 |
(1) | Interest payments on long-term debt are calculated on outstanding balances and interest rates in effect on December 31, 2014. |
• | Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription is delivered. At the time of delivery, the Pharmacy Services Segment has performed substantially all of its obligations under its client contracts and does not experience a significant level of returns or reshipments. |
• | Revenues generated from prescription drugs sold by third party pharmacies in the Pharmacy Services Segment’s retail pharmacy network and associated administrative fees are recognized at the Pharmacy Services Segment’s point-of-sale, which is when the claim is adjudicated by the Pharmacy Services Segment’s online claims processing system. |
• | Risks relating to the health of the economy in general and in the markets we serve, which could impact consumer purchasing power, preferences and/or spending patterns, drug utilization trends, the financial health of our PBM clients or other payors doing business with the Company and our ability to secure necessary financing, suitable store locations and sale-leaseback transactions on acceptable terms. |
• | Efforts to reduce reimbursement levels and alter health care financing practices, including pressure to reduce reimbursement levels for generic drugs. |
• | The possibility of PBM client loss and/or the failure to win new PBM business, including as a result of failure to win renewal of expiring contracts, contract termination rights that may permit clients to terminate a contract prior to expiration and early or periodic renegotiation of pricing by clients prior to expiration of a contract. |
• | The possibility of loss of Medicare Part D business and/or failure to obtain new Medicare Part D business, whether as a result of the annual Medicare Part D competitive bidding process or otherwise. |
• | Risks related to the frequency and rate of the introduction of generic drugs and brand name prescription products. |
• | Risks of declining gross margins in the PBM industry attributable to increased competitive pressures, increased client demand for lower prices, enhanced service offerings and/or higher service levels and market dynamics and regulatory changes that impact our ability to offer plan sponsors pricing that includes the use of retail “differential” or “spread.” |
• | Regulatory changes, business changes and compliance requirements and restrictions that may be imposed by Centers for Medicare and Medicaid Services (“CMS”), Office of Inspector General or other government agencies relating to the Company’s participation in Medicare, Medicaid and other federal and state government-funded programs, including sanctions and remedial actions that may be imposed by CMS on its Medicare Part D business. |
• | Risks and uncertainties related to the timing and scope of reimbursement from Medicare, Medicaid and other government-funded programs, including the impact of sequestration, the impact of other federal budget, debt and deficit negotiations and legislation that could delay or reduce reimbursement from such programs and the impact of any closure, suspension or other changes affecting federal or state government funding or operations. |
• | Possible changes in industry pricing benchmarks used to establish pricing in many of our PBM client contracts, pharmaceutical purchasing arrangements, retail network contracts, specialty payor agreements and other third party payor contracts. |
• | A highly competitive business environment, including the uncertain impact of increased consolidation in the PBM industry, uncertainty concerning the ability of our retail pharmacy business to secure and maintain contractual relationships with PBMs and other payors on acceptable terms, uncertainty concerning the ability of our PBM business to secure and maintain competitive access, pricing and other contract terms from retail network pharmacies in an environment where some PBM clients are willing to consider adopting narrow or more restricted retail pharmacy networks. |
• | The Company’s ability to fully integrate and to realize the planned benefits associated with the acquisition of Coram LLC in accordance with the expected timing. |
• | The Company’s ability to timely identify or effectively respond to changing consumer preferences and spending patterns, an inability to expand the products being purchased by our customers, or the failure or inability to obtain or offer particular categories of products. |
• | Risks relating to our ability to secure timely and sufficient access to the products we sell from our domestic and/or international suppliers. |
• | Reform of the U.S. health care system, including ongoing implementation of ACA, continuing legislative efforts, regulatory changes and judicial interpretations impacting our health care system and the possibility of shifting political and legislative priorities related to reform of the health care system in the future. |
• | Risks relating to any failure to properly maintain our information technology systems, our information security systems and our infrastructure to support our business and to protect the privacy and security of sensitive customer and business information. |
• | Risks related to compliance with a broad and complex regulatory framework, including compliance with new and existing federal, state and local laws and regulations relating to health care, accounting standards, corporate securities, tax, environmental and other laws and regulations affecting our business. |
• | Risks related to litigation, government investigations and other legal proceedings as they relate to our business, the pharmacy services, retail pharmacy or retail clinic industries or to the health care industry generally. |
• | Other risks and uncertainties detailed from time to time in our filings with the SEC. |
/s/ Ernst & Young LLP | |
Boston, Massachusetts | |
February 10, 2015 |
Year Ended December 31, | |||||||||||
In millions, except per share amounts | 2014 | 2013 | 2012 | ||||||||
Net revenues | $ | 139,367 | $ | 126,761 | $ | 123,120 | |||||
Cost of revenues | 114,000 | 102,978 | 100,632 | ||||||||
Gross profit | 25,367 | 23,783 | 22,488 | ||||||||
Operating expenses | 16,568 | 15,746 | 15,278 | ||||||||
Operating profit | 8,799 | 8,037 | 7,210 | ||||||||
Interest expense, net | 600 | 509 | 557 | ||||||||
Loss on early extinguishment of debt | 521 | — | 348 | ||||||||
Income before income tax provision | 7,678 | 7,528 | 6,305 | ||||||||
Income tax provision | 3,033 | 2,928 | 2,436 | ||||||||
Income from continuing operations | 4,645 | 4,600 | 3,869 | ||||||||
Loss from discontinued operations, net of tax | (1 | ) | (8 | ) | (7 | ) | |||||
Net income | 4,644 | 4,592 | 3,862 | ||||||||
Net loss attributable to noncontrolling interest | — | — | 2 | ||||||||
Net income attributable to CVS Health | $ | 4,644 | $ | 4,592 | $ | 3,864 | |||||
Basic earnings per share: | |||||||||||
Income from continuing operations attributable to CVS Health | $ | 3.98 | $ | 3.78 | $ | 3.05 | |||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | (0.01 | ) | $ | (0.01 | ) | |||
Net income attributable to CVS Health | $ | 3.98 | $ | 3.77 | $ | 3.04 | |||||
Weighted average shares outstanding | 1,161 | 1,217 | 1,271 | ||||||||
Diluted earnings per share: | |||||||||||
Income from continuing operations attributable to CVS Health | $ | 3.96 | $ | 3.75 | $ | 3.02 | |||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | (0.01 | ) | $ | (0.01 | ) | |||
Net income attributable to CVS Health | $ | 3.96 | $ | 3.74 | $ | 3.02 | |||||
Weighted average shares outstanding | 1,169 | 1,226 | 1,280 | ||||||||
Dividends declared per share | $ | 1.10 | $ | 0.90 | $ | 0.65 |
Year Ended December 31, | |||||||||||
In millions | 2014 | 2013 | 2012 | ||||||||
Net income | $ | 4,644 | $ | 4,592 | $ | 3,862 | |||||
Other comprehensive income (loss): | |||||||||||
Foreign currency translation adjustments, net of tax | (35 | ) | (30 | ) | — | ||||||
Net cash flow hedges, net of tax | 4 | 3 | 3 | ||||||||
Pension and other postretirement benefits, net of tax | (37 | ) | 59 | (12 | ) | ||||||
Total other comprehensive income (loss) | (68 | ) | 32 | (9 | ) | ||||||
Comprehensive income | 4,576 | 4,624 | 3,853 | ||||||||
Comprehensive loss attributable to noncontrolling interest | — | — | 2 | ||||||||
Comprehensive income attributable to CVS Health | $ | 4,576 | $ | 4,624 | $ | 3,855 |
December 31, | |||||||
In millions, except per share amounts | 2014 | 2013 | |||||
Assets: | |||||||
Cash and cash equivalents | $ | 2,481 | $ | 4,089 | |||
Short-term investments | 34 | 88 | |||||
Accounts receivable, net | 9,687 | 8,729 | |||||
Inventories | 11,930 | 11,045 | |||||
Deferred income taxes | 985 | 902 | |||||
Other current assets | 866 | 472 | |||||
Total current assets | 25,983 | 25,325 | |||||
Property and equipment, net | 8,843 | 8,615 | |||||
Goodwill | 28,142 | 26,542 | |||||
Intangible assets, net | 9,774 | 9,529 | |||||
Other assets | 1,510 | 1,515 | |||||
Total assets | $ | 74,252 | $ | 71,526 | |||
Liabilities: | |||||||
Accounts payable | $ | 6,547 | $ | 5,548 | |||
Claims and discounts payable | 5,404 | 4,548 | |||||
Accrued expenses | 5,816 | 4,768 | |||||
Short-term debt | 685 | — | |||||
Current portion of long-term debt | 575 | 561 | |||||
Total current liabilities | 19,027 | 15,425 | |||||
Long-term debt | 11,695 | 12,841 | |||||
Deferred income taxes | 4,036 | 3,901 | |||||
Other long-term liabilities | 1,531 | 1,421 | |||||
Commitments and contingencies (Note 11) | — | — | |||||
Shareholders’ equity: | |||||||
CVS Health shareholders’ equity: | |||||||
Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding | — | — | |||||
Common stock, par value $0.01: 3,200 shares authorized; 1,691 shares issued and 1,140 | |||||||
shares outstanding at December 31, 2014 and 1,680 shares issued and 1,180 shares | |||||||
outstanding at December 31, 2013 | 17 | 17 | |||||
Treasury stock, at cost: 550 shares at December 31, 2014 and 500 shares at December 31, | |||||||
2013 | (24,078 | ) | (20,169 | ) | |||
Shares held in trust: 1 share at December 31, 2014 and 2013 | (31 | ) | (31 | ) | |||
Capital surplus | 30,418 | 29,777 | |||||
Retained earnings | 31,849 | 28,493 | |||||
Accumulated other comprehensive income (loss) | (217 | ) | (149 | ) | |||
Total CVS Health shareholders’ equity | 37,958 | 37,938 | |||||
Noncontrolling interest | 5 | — | |||||
Total shareholders’ equity | 37,963 | 37,938 | |||||
Total liabilities and shareholders’ equity | $ | 74,252 | $ | 71,526 |
Year Ended December 31, | |||||||||||
In millions | 2014 | 2013 | 2012 | ||||||||
Cash flows from operating activities: | |||||||||||
Cash receipts from customers | $ | 132,406 | $ | 114,993 | $ | 113,205 | |||||
Cash paid for inventory and prescriptions dispensed by retail network pharmacies | (105,362 | ) | (91,178 | ) | (90,032 | ) | |||||
Cash paid to other suppliers and employees | (15,344 | ) | (14,295 | ) | (13,643 | ) | |||||
Interest received | 15 | 8 | 4 | ||||||||
Interest paid | (647 | ) | (534 | ) | (581 | ) | |||||
Income taxes paid | (2,931 | ) | (3,211 | ) | (2,282 | ) | |||||
Net cash provided by operating activities | 8,137 | 5,783 | 6,671 | ||||||||
Cash flows from investing activities: | |||||||||||
Purchases of property and equipment | (2,136 | ) | (1,984 | ) | (2,030 | ) | |||||
Proceeds from sale-leaseback transactions | 515 | 600 | 529 | ||||||||
Proceeds from sale of property and equipment and other assets | 11 | 54 | 23 | ||||||||
Acquisitions (net of cash acquired) and other investments | (2,439 | ) | (415 | ) | (378 | ) | |||||
Purchase of available-for-sale investments | (157 | ) | (226 | ) | — | ||||||
Maturity of available-for-sale investments | 161 | 136 | — | ||||||||
Proceeds from sale of subsidiary | — | — | 7 | ||||||||
Net cash used in investing activities | (4,045 | ) | (1,835 | ) | (1,849 | ) | |||||
Cash flows from financing activities: | |||||||||||
Increase (decrease) in short-term debt | 685 | (690 | ) | (60 | ) | ||||||
Proceeds from issuance of long-term debt | 1,483 | 3,964 | 1,239 | ||||||||
Repayments of long-term debt | (3,100 | ) | — | (1,718 | ) | ||||||
Purchase of noncontrolling interest in subsidiary | — | — | (26 | ) | |||||||
Dividends paid | (1,288 | ) | (1,097 | ) | (829 | ) | |||||
Proceeds from exercise of stock options | 421 | 500 | 836 | ||||||||
Excess tax benefits from stock-based compensation | 106 | 62 | 28 | ||||||||
Repurchase of common stock | (4,001 | ) | (3,976 | ) | (4,330 | ) | |||||
Net cash used in financing activities | (5,694 | ) | (1,237 | ) | (4,860 | ) | |||||
Effect of exchange rate changes on cash and cash equivalents | (6 | ) | 3 | — | |||||||
Net increase (decrease) in cash and cash equivalents | (1,608 | ) | 2,714 | (38 | ) | ||||||
Cash and cash equivalents at the beginning of the year | 4,089 | 1,375 | 1,413 | ||||||||
Cash and cash equivalents at the end of the year | $ | 2,481 | $ | 4,089 | $ | 1,375 | |||||
Reconciliation of net income to net cash provided by operating activities: | |||||||||||
Net income | $ | 4,644 | $ | 4,592 | $ | 3,862 | |||||
Adjustments required to reconcile net income to net cash provided by operating activities: | |||||||||||
Depreciation and amortization | 1,931 | 1,870 | 1,753 | ||||||||
Stock-based compensation | 165 | 141 | 132 | ||||||||
Loss on early extinguishment of debt | 521 | — | 348 | ||||||||
Deferred income taxes and other noncash items | (58 | ) | (86 | ) | (111 | ) | |||||
Change in operating assets and liabilities, net of effects from acquisitions: | |||||||||||
Accounts receivable, net | (737 | ) | (2,210 | ) | (387 | ) | |||||
Inventories | (770 | ) | 12 | (853 | ) | ||||||
Other current assets | (383 | ) | 105 | 3 | |||||||
Other assets | 9 | (135 | ) | (99 | ) | ||||||
Accounts payable and claims and discounts payable | 1,742 | 1,024 | 1,147 | ||||||||
Accrued expenses | 1,060 | 471 | 766 | ||||||||
Other long-term liabilities | 13 | (1 | ) | 110 | |||||||
Net cash provided by operating activities | $ | 8,137 | $ | 5,783 | $ | 6,671 |
Shares | Dollars | |||||||||||||||||||
Year Ended December 31, | Year Ended December 31, | |||||||||||||||||||
In millions | 2014 | 2013 | 2012 | 2014 | 2013 | 2012 | ||||||||||||||
Common stock: | ||||||||||||||||||||
Beginning of year | 1,680 | 1,667 | 1,640 | $ | 17 | $ | 17 | $ | 16 | |||||||||||
Stock options exercised and issuance of stock awards | 11 | 13 | 27 | — | — | 1 | ||||||||||||||
End of year | 1,691 | 1,680 | 1,667 | $ | 17 | $ | 17 | $ | 17 | |||||||||||
Treasury stock: | ||||||||||||||||||||
Beginning of year | (500 | ) | (435 | ) | (340 | ) | $ | (20,169 | ) | $ | (16,270 | ) | $ | (11,953 | ) | |||||
Purchase of treasury shares | (51 | ) | (66 | ) | (95 | ) | (4,001 | ) | (3,976 | ) | (4,330 | ) | ||||||||
Employee stock purchase plan issuances | 1 | 1 | 1 | 92 | 77 | 47 | ||||||||||||||
Transfer of shares from shares held in trust | — | — | (1 | ) | — | — | (34 | ) | ||||||||||||
End of year | (550 | ) | (500 | ) | (435 | ) | $ | (24,078 | ) | $ | (20,169 | ) | $ | (16,270 | ) | |||||
Shares held in trust: | ||||||||||||||||||||
Beginning of year | (1 | ) | (1 | ) | (2 | ) | $ | (31 | ) | $ | (31 | ) | $ | (56 | ) | |||||
Transfer of shares to treasury stock | — | — | 1 | — | — | 25 | ||||||||||||||
End of year | (1 | ) | (1 | ) | (1 | ) | $ | (31 | ) | $ | (31 | ) | $ | (31 | ) | |||||
Capital surplus: | ||||||||||||||||||||
Beginning of year | $ | 29,777 | $ | 29,120 | $ | 28,126 | ||||||||||||||
Stock option activity and stock awards | 535 | 588 | 955 | |||||||||||||||||
Excess tax benefit on stock options and stock awards | 106 | 69 | 28 | |||||||||||||||||
Transfer of shares held in trust to treasury stock | — | — | 9 | |||||||||||||||||
Purchase of noncontrolling interest in subsidiary | — | — | 2 | |||||||||||||||||
End of year | $ | 30,418 | $ | 29,777 | $ | 29,120 | ||||||||||||||
Retained earnings: | ||||||||||||||||||||
Beginning of year | $ | 28,493 | $ | 24,998 | $ | 22,052 | ||||||||||||||
Changes in inventory accounting principles | — | — | (89 | ) | ||||||||||||||||
Net income attributable to CVS Health | 4,644 | 4,592 | 3,864 | |||||||||||||||||
Common stock dividends | (1,288 | ) | (1,097 | ) | (829 | ) | ||||||||||||||
End of year | $ | 31,849 | $ | 28,493 | $ | 24,998 | ||||||||||||||
Accumulated other comprehensive loss: | ||||||||||||||||||||
Beginning of year | $ | (149 | ) | $ | (181 | ) | $ | (172 | ) | |||||||||||
Foreign currency translation adjustments, net of tax | (35 | ) | (30 | ) | — | |||||||||||||||
Net cash flow hedges, net of tax | 4 | 3 | 3 | |||||||||||||||||
Pension and other postretirement benefits, net of tax | (37 | ) | 59 | (12 | ) | |||||||||||||||
End of year | $ | (217 | ) | $ | (149 | ) | $ | (181 | ) | |||||||||||
Total CVS Health shareholders’ equity | $ | 37,958 | $ | 37,938 | $ | 37,653 | ||||||||||||||
Noncontrolling interest: | ||||||||||||||||||||
Beginning of year | $ | — | $ | — | $ | — | ||||||||||||||
Business combinations | 5 | — | — | |||||||||||||||||
End of year | $ | 5 | $ | — | $ | — | ||||||||||||||
Total shareholders’ equity | $ | 37,963 | $ | 37,938 | $ | 37,653 |
• | Level 1 - Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. |
• | Level 2 - Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument. |
• | Level 3 - Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk. |
In millions | 2014 | 2013 | 2012 | ||||||||
Beginning balance | $ | 256 | $ | 243 | $ | 189 | |||||
Additions charged to bad debt expense | 185 | 195 | 149 | ||||||||
Write-offs charged to allowance | (185 | ) | (182 | ) | (95 | ) | |||||
Ending balance | $ | 256 | $ | 256 | $ | 243 |
In millions | 2014 | 2013 | |||||
Land | $ | 1,506 | $ | 1,460 | |||
Building and improvements | 2,828 | 2,694 | |||||
Fixtures and equipment | 8,958 | 8,419 | |||||
Leasehold improvements | 3,626 | 3,320 | |||||
Software | 1,868 | 1,515 | |||||
18,786 | 17,408 | ||||||
Accumulated depreciation and amortization | (9,943 | ) | (8,793 | ) | |||
Property and equipment, net | $ | 8,843 | $ | 8,615 |
In millions | |||
Balance, December 31, 2011 | $ | 30 | |
Net loss attributable to noncontrolling interest | (2 | ) | |
Purchase of noncontrolling interest | (26 | ) | |
Reclassification to capital surplus in connection with purchase of | |||
noncontrolling interest | (2 | ) | |
Balance, December 31, 2012 | $ | — |
• | Revenues generated from prescription drugs sold by mail service dispensing pharmacies are recognized when the prescription is delivered. At the time of delivery, the PSS has performed substantially all of its obligations under its client contracts and does not experience a significant level of returns or reshipments. |
• | Revenues generated from prescription drugs sold by third party pharmacies in the PSS’ retail pharmacy network and associated administrative fees are recognized at the PSS’ point-of-sale, which is when the claim is adjudicated by the PSS online claims processing system. |
Year Ended December 31, 2014(1) | |||||||||||||||
In millions | Foreign Currency | Losses on Cash Flow Hedges | Pension and Other Postretirement Benefits | Total | |||||||||||
Balance, December 31, 2013 | $ | (30 | ) | $ | (13 | ) | $ | (106 | ) | $ | (149 | ) | |||
Other comprehensive income (loss) before reclassifications | (35 | ) | — | — | (35 | ) | |||||||||
Amounts reclassified from accumulated other comprehensive income (2) | — | 4 | (37 | ) | (33 | ) | |||||||||
Net other comprehensive income (loss) | (35 | ) | 4 | (37 | ) | (68 | ) | ||||||||
Balance, December 31, 2014 | $ | (65 | ) | $ | (9 | ) | $ | (143 | ) | $ | (217 | ) | |||
Year Ended December 31, 2013(1) | |||||||||||||||
Foreign Currency | Losses on Cash Flow Hedges | Pension and Other Postretirement Benefits | Total | ||||||||||||
Balance, December 31, 2012 | $ | — | $ | (16 | ) | $ | (165 | ) | $ | (181 | ) | ||||
Other comprehensive income (loss) before reclassifications | (30 | ) | — | — | (30 | ) | |||||||||
Amounts reclassified from accumulated other comprehensive income (2) | — | 3 | 59 | 62 | |||||||||||
Net other comprehensive income (loss) | (30 | ) | 3 | 59 | 32 | ||||||||||
Balance, December 31, 2013 | $ | (30 | ) | $ | (13 | ) | $ | (106 | ) | $ | (149 | ) |
(1) | All amounts are net of tax. |
(2) | The amounts reclassified from accumulated other comprehensive income for cash flow hedges are recorded within interest expense, net on the consolidated statement of income. The amounts reclassified from accumulated other comprehensive income for pension and other postretirement benefits are included in operating expenses on the consolidated statement of income. |
In millions | 2014 | 2013 | 2012 | |||||||||
Loss on disposal | $ | (1 | ) | $ | (12 | ) | $ | (12 | ) | |||
Income tax benefit | — | 4 | 5 | |||||||||
Loss from discontinued operations, net of tax | $ | (1 | ) | $ | (8 | ) | $ | (7 | ) |
In millions | |||
Accounts receivable | $ | 215 | |
Inventory | 77 | ||
Other assets | 10 | ||
Property and equipment | 49 | ||
Intangible assets | 537 | ||
Goodwill | 1,566 | ||
Current liabilities | (128 | ) | |
Deferred tax liabilities, net | (97 | ) | |
Other noncurrent liabilities | (91 | ) | |
Noncontrolling interest | (2 | ) | |
Total consideration | $ | 2,136 |
In millions | Pharmacy Services | Retail Pharmacy | Total | ||||||||
Balance, December 31, 2012 | $ | 19,646 | $ | 6,749 | $ | 26,395 | |||||
Acquisitions | 13 | 160 | 173 | ||||||||
Foreign currency translation adjustments | — | (25 | ) | (25 | ) | ||||||
Other (1) | (1 | ) | — | (1 | ) | ||||||
Balance, December 31, 2013 | 19,658 | 6,884 | 26,542 | ||||||||
Acquisitions | 1,578 | 38 | 1,616 | ||||||||
Foreign currency translation adjustments | — | (14 | ) | (14 | ) | ||||||
Other (1) | (2 | ) | — | (2 | ) | ||||||
Balance, December 31, 2014 | $ | 21,234 | $ | 6,908 | $ | 28,142 |
In millions | |||
2015 | $ | 486 | |
2016 | $ | 456 | |
2017 | $ | 433 | |
2018 | $ | 415 | |
2019 | $ | 383 |
2014 | 2013 | ||||||||||||||||||||||
In millions | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | |||||||||||||||||
Trademark (indefinitely-lived) | $ | 6,398 | $ | — | $ | 6,398 | $ | 6,398 | $ | — | $ | 6,398 | |||||||||||
Customer contracts and relationships and covenants not to compete | 6,521 | (3,549 | ) | 2,972 | 5,840 | (3,083 | ) | 2,757 | |||||||||||||||
Favorable leases and other | 880 | (476 | ) | 404 | 800 | (426 | ) | 374 | |||||||||||||||
$ | 13,799 | $ | (4,025 | ) | $ | 9,774 | $ | 13,038 | $ | (3,509 | ) | $ | 9,529 |
Authorization Date | Amount of Authorization | ||
In billions | |||
December 15, 2014 (“2014 Repurchase Program”) | $ | 10.0 | |
December 17, 2013 (“2013 Repurchase Program”) | $ | 6.0 | |
September 19, 2012 (“2012 Repurchase Program”) | $ | 6.0 | |
August 23, 2011 (“2011 Repurchase Program”) | $ | 4.0 |
In millions | 2014 | 2013 | |||||
Commercial paper | $ | 685 | $ | — | |||
4.875% senior notes due 2014 | — | 550 | |||||
3.25% senior notes due 2015 | 550 | 550 | |||||
6.125% senior notes due 2016 | 421 | 421 | |||||
1.2% senior notes due 2016 | 750 | 750 | |||||
5.75% senior notes due 2017 | 1,080 | 1,310 | |||||
2.25% senior notes due 2018 | 1,250 | 1,250 | |||||
6.6% senior notes due 2019 | 394 | 394 | |||||
2.25% senior notes due 2019 | 850 | — | |||||
4.75% senior notes due 2020 | 450 | 450 | |||||
4.125% senior notes due 2021 | 550 | 550 | |||||
2.75% senior notes due 2022 | 1,250 | 1,250 | |||||
4.0% senior notes due 2023 | 1,250 | 1,250 | |||||
3.375% senior notes due 2024 | 650 | — | |||||
6.25% senior notes due 2027 | 453 | 1,000 | |||||
6.125% senior notes due 2039 | 734 | 1,500 | |||||
5.75% senior notes due 2041 | 493 | 950 | |||||
5.3% senior notes due 2043 | 750 | 750 | |||||
Capital lease obligations | 391 | 390 | |||||
Other | 4 | 87 | |||||
12,955 | 13,402 | ||||||
Less: | |||||||
Short-term debt (commercial paper) | (685 | ) | — | ||||
Current portion of long-term debt | (575 | ) | (561 | ) | |||
Long-term debt | $ | 11,695 | $ | 12,841 |
In millions | 2014 | 2013 | 2012 | ||||||||
Minimum rentals | $ | 2,320 | $ | 2,210 | $ | 2,165 | |||||
Contingent rentals | 36 | 41 | 48 | ||||||||
2,356 | 2,251 | 2,213 | |||||||||
Less: sublease income | (21 | ) | (21 | ) | (20 | ) | |||||
$ | 2,335 | $ | 2,230 | $ | 2,193 |
In millions | Capital Leases | Operating Leases(1) | |||||
2015 | $ | 47 | $ | 2,279 | |||
2016 | 47 | 2,220 | |||||
2017 | 47 | 2,121 | |||||
2018 | 48 | 2,007 | |||||
2019 | 48 | 1,861 | |||||
Thereafter | 573 | 16,794 | |||||
Total future lease payments | 810 | $ | 27,282 | ||||
Less: imputed interest | (419 | ) | |||||
Present value of capital lease obligations | $ | 391 |
(1) | Future operating lease payments have not been reduced by minimum sublease rentals of $203 million due in the future under noncancelable subleases. |
2014 | 2013 | 2012 | |||||||||
Dividend yield(1) | 0.75 | % | 0.86 | % | 0.73 | % | |||||
Expected volatility(2) | 14.87 | % | 16.94 | % | 22.88 | % | |||||
Risk-free interest rate(3) | 0.08 | % | 0.10 | % | 0.10 | % | |||||
Expected life (in years)(4) | 0.5 | 0.5 | 0.5 | ||||||||
Weighted-average grant date fair value | $ | 13.74 | $ | 10.08 | $ | 9.22 |
(1) | The dividend yield is calculated based on semi-annual dividends paid and the fair market value of the Company’s stock at the grant date. |
(2) | The expected volatility is based on the historical volatility of the Company’s daily stock market prices over the previous six month period. |
(3) | The risk-free interest rate is based on the Treasury constant maturity interest rate whose term is consistent with the expected term of ESPP options (i.e., 6 months). |
(4) | The expected life is based on the semi-annual purchase period. |
Units in thousands | Units | Weighted Average Grant Date Fair Value | ||||
Nonvested at beginning of year | 3,021 | $ | 38.56 | |||
Granted | 2,708 | $ | 73.60 | |||
Vested | (803 | ) | $ | 73.11 | ||
Forfeited | (249 | ) | $ | 57.58 | ||
Nonvested at end of year | 4,677 | $ | 51.90 |
2014 | 2013 | 2012 | |||||||||
Dividend yield(1) | 1.47 | % | 1.65 | % | 1.44 | % | |||||
Expected volatility(2) | 19.92 | % | 30.96 | % | 32.49 | % | |||||
Risk-free interest rate(3) | 1.35 | % | 0.73 | % | 0.84 | % | |||||
Expected life (in years)(4) | 4.0 | 4.7 | 4.7 | ||||||||
Weighted-average grant date fair value | $ | 11.04 | $ | 12.50 | $ | 11.12 |
(1) | The dividend yield is based on annual dividends paid and the fair market value of the Company’s stock at the grant date. |
(2) | The expected volatility is estimated using the Company’s historical volatility over a period equal to the expected life of each option grant after adjustments for infrequent events such as stock splits. |
(3) | The risk-free interest rate is selected based on yields from U.S. Treasury zero-coupon issues with a remaining term equal to the expected term of the options being valued. |
(4) | The expected life represents the number of years the options are expected to be outstanding from grant date based on historical option holder exercise experience. |
Shares in thousands | Shares | Weighted Average Exercise Price | Weighted Average Remaining Contractual Term | Aggregate Intrinsic Value | ||||||||
Outstanding at December 31, 2013 | 34,738 | $ | 41.40 | |||||||||
Granted | 4,525 | $ | 74.96 | |||||||||
Exercised | (9,563 | ) | $ | 37.30 | ||||||||
Forfeited | (1,202 | ) | $ | 50.15 | ||||||||
Expired | (332 | ) | $ | 36.93 | ||||||||
Outstanding at December 31, 2014 | 28,166 | $ | 47.87 | 4.15 | $ | 1,364,408,886 | ||||||
Exercisable at December 31, 2014 | 11,634 | $ | 37.86 | 2.82 | $ | 679,995,090 | ||||||
Vested at December 31, 2014 and expected to vest in the future | 27,394 | $ | 47.51 | 4.11 | $ | 1,336,774,863 |
In millions | 2014 | 2013 | 2012 | ||||||||
Current: | |||||||||||
Federal | $ | 2,581 | $ | 2,623 | $ | 2,226 | |||||
State | 495 | 437 | 410 | ||||||||
3,076 | 3,060 | 2,636 | |||||||||
Deferred: | |||||||||||
Federal | (43 | ) | (115 | ) | (182 | ) | |||||
State | — | (17 | ) | (18 | ) | ||||||
(43 | ) | (132 | ) | (200 | ) | ||||||
Total | $ | 3,033 | $ | 2,928 | $ | 2,436 |
2014 | 2013 | 2012 | ||||||
Statutory income tax rate | 35.0 | % | 35.0 | % | 35.0 | % | ||
State income taxes, net of federal tax benefit | 4.3 | 4.0 | 3.9 | |||||
Other | 0.2 | (0.1 | ) | (0.3 | ) | |||
Effective income tax rate | 39.5 | % | 38.9 | % | 38.6 | % |
In millions | 2014 | 2013 | |||||
Deferred tax assets: | |||||||
Lease and rents | $ | 396 | $ | 344 | |||
Employee benefits | 311 | 213 | |||||
Allowance for doubtful accounts | 164 | 172 | |||||
Retirement benefits | 80 | 79 | |||||
Net operating losses | 74 | 10 | |||||
Depreciation | — | 192 | |||||
Deferred income | 261 | 220 | |||||
Other | 297 | 378 | |||||
Valuation allowance | (5 | ) | (3 | ) | |||
Total deferred tax assets | 1,578 | 1,605 | |||||
Deferred tax liabilities: | |||||||
Inventories | (18 | ) | (69 | ) | |||
Depreciation and amortization | (4,572 | ) | (4,512 | ) | |||
Total deferred tax liabilities | (4,590 | ) | (4,581 | ) | |||
Net deferred tax liabilities | $ | (3,012 | ) | $ | (2,976 | ) |
In millions | 2014 | 2013 | |||||
Deferred tax assets—current | $ | 985 | $ | 902 | |||
Deferred tax assets—noncurrent (included in other assets) | 39 | 23 | |||||
Deferred tax liabilities—noncurrent | (4,036 | ) | (3,901 | ) | |||
Net deferred tax liabilities | $ | (3,012 | ) | $ | (2,976 | ) |
In millions | 2014 | 2013 | 2012 | ||||||||
Beginning balance | $ | 117 | $ | 80 | $ | 38 | |||||
Additions based on tax positions related to the current year | 32 | 19 | 15 | ||||||||
Additions based on tax positions related to prior years | 70 | 37 | 42 | ||||||||
Reductions for tax positions of prior years | (15 | ) | (1 | ) | (2 | ) | |||||
Expiration of statutes of limitation | (15 | ) | (17 | ) | (12 | ) | |||||
Settlements | (1 | ) | (1 | ) | (1 | ) | |||||
Ending balance | $ | 188 | $ | 117 | $ | 80 |
• | In December 2007, the Company received a document subpoena from the Office of Inspector General (“OIG”) within the U.S. Department of Health and Human Services, requesting information relating to the processing of Medicaid and certain other government agency claims on behalf of its clients (which allegedly resulted in underpayments from our pharmacy benefit management clients to the applicable government agencies) on one of the Company’s adjudication platforms. In September 2014, the Company settled the OIG’s claims, as well as related claims by the Department of Justice and private plaintiffs, without any admission of liability. The Company is in discussions with the OIG concerning other claim processing issues. |
• | Caremark (the term “Caremark” being used herein to generally refer to any one or more PBM subsidiaries of the Company, as applicable) was named in a putative class action lawsuit filed in October 2003 in Alabama state court by John Lauriello, purportedly on behalf of participants in the 1999 settlement of various securities class action and derivative lawsuits against Caremark and others. Other defendants include insurance companies that provided coverage to Caremark with respect to the settled lawsuits. The Lauriello lawsuit seeks approximately $3.2 billion in compensatory damages plus other non-specified damages based on allegations that the amount of insurance coverage available for the settled lawsuits was misrepresented and suppressed. A similar lawsuit was filed in November 2003 by Frank McArthur, also in Alabama state court, naming as defendants, among others, Caremark and several insurance companies involved in the 1999 settlement. This lawsuit was stayed as a later-filed class action, but McArthur was subsequently allowed to intervene in the Lauriello action. Following the close of class discovery, the trial court entered an Order on August 15, 2012 that granted the plaintiffs’ motion to certify a class pursuant to Alabama Rule of Civil Procedures 23(b)(3) but denied their request that the class also be certified pursuant to Rule 23(b)(1). In addition, the August 15, 2012 Order appointed class representatives and class counsel. On September 12, 2014, the Alabama Supreme Court affirmed the trial court’s August 15, 2012 Order. The Defendants timely filed an Application for Rehearing asking the Alabama Supreme Court to clarify or modify its September 12, 2014 decision. The proceedings in the trial court remain stayed pending resolution of the rehearing application. |
• | Various lawsuits have been filed alleging that Caremark has violated applicable antitrust laws in establishing and maintaining retail pharmacy networks for client health plans. In August 2003, Bellevue Drug Co., Robert Schreiber, Inc. d/b/a Burns Pharmacy and Rehn-Huerbinger Drug Co. d/b/a Parkway Drugs #4, together with Pharmacy Freedom Fund and the National Community Pharmacists Association filed a putative class action against Caremark in Pennsylvania federal court, seeking treble damages and injunctive relief. This case was initially sent to arbitration based on the contract terms between the pharmacies and Caremark. In October 2003, two independent pharmacies, North Jackson Pharmacy, Inc. and C&C, Inc. d/b/a Big C Discount Drugs, Inc., filed a putative class action complaint in Alabama federal court against Caremark and two PBM competitors, seeking treble damages and injunctive relief. The North Jackson Pharmacy case against two of the Caremark entities named as defendants was transferred to Illinois federal court, and the case against a separate Caremark entity was sent to arbitration based on contract terms between the pharmacies and Caremark. The Bellevue arbitration was then stayed by the parties pending developments in the North Jackson Pharmacy court case. |
• | In November 2009, a securities class action lawsuit was filed in the United States District Court for the District of Rhode Island by Richard Medoff, purportedly on behalf of purchasers of CVS Health Corporation stock between |
• | In March 2010, the Company learned that various State Attorneys General offices and certain other government agencies were conducting a multi-state investigation of certain of the Company’s business practices similar to those being investigated at that time by the U.S. Federal Trade Commission (“FTC”). Twenty-eight states, the District of Columbia and the County of Los Angeles are known to be participating in this investigation. The prior FTC investigation, which commenced in August 2009, was officially concluded in May 2012 when the consent order entered into between the FTC and the Company became final. The Company has cooperated with the multi-state investigation. |
• | In March 2010, the Company received a subpoena from the OIG requesting information about programs under which the Company has offered customers remuneration conditioned upon the transfer of prescriptions for drugs or medications to the Company’s pharmacies in the form of gift cards, cash, non-prescription merchandise or discounts or coupons for non-prescription merchandise. The subpoena relates to an investigation of possible false or otherwise improper claims for payment under the Medicare and Medicaid programs. The Company has provided documents and other information in response to this request for information. |
• | In January 2012, the United States District Court for the Eastern District of Pennsylvania unsealed a first amended qui tam complaint filed in August 2011 by an individual relator, Anthony Spay, who is described in the complaint as having once been employed by a firm providing pharmacy prescription benefit audit and recovery services. The complaint seeks monetary damages and alleges that Caremark’s processing of Medicare claims on behalf of one of its clients violated the federal False Claims Act. The United States declined to intervene in the lawsuit. The case is proceeding. |
• | In November 2014, the U.S. District Court in the District of Massachusetts unsealed a qui tam lawsuit brought against the Company by a pharmacy auditor and a CVS pharmacist. The lawsuit, which was initially filed under seal in 2011, alleges that the Company violated the federal False Claims Act, as well as the false claims acts of several states, by overcharging state and federal governments in connection with prescription drugs available through the Company’s Health Savings Pass program, a membership-based program that allows enrolled customers special pricing for typical 90-day supplies of various generic prescription drugs. The federal government, which issued a January 2012 OIG subpoena concerning the Health Savings Pass program, has declined to intervene in the case. The Company is now responding to the declined qui tam complaint. Separately, the Attorney General of the State of Texas has issued civil investigative demands and other requests in February 2012 and May 2014, and has continued its investigation concerning the Health Savings Pass program and claims for reimbursement from the Texas Medicaid program. |
• | On October 12, 2012, the Drug Enforcement Agency (“DEA”) Administrator published its Final Decision and Order revoking the DEA license registrations for dispensing controlled substances at two of our retail pharmacy stores in Sanford, Florida. The license revocations for the two stores formally became effective on November 13, 2012. The Company has entered into discussions with the U.S. Attorney’s Office for the Middle District of Florida concerning civil penalties for violations of the Controlled Substances Act arising from the circumstances underlying the action taken against the two Sanford, Florida stores. The Company is also undergoing several audits by the DEA and is in discussions with the DEA and the U.S. Attorney’s Office in several locations. Whether agreements can be reached and on what terms is uncertain. |
• | In November 2012, the Company received a subpoena from the OIG requesting information concerning automatic refill programs used by pharmacies to refill prescriptions for customers. The Company has been cooperating and providing documents and other information in response to this request for information. |
• | In January 2014, the U.S. District Court in the Southern District of New York unsealed a qui tam action in which the Company is a defendant. The suit originally was filed under seal in 2011 by relator David Kester, a former employee of Novartis Pharmaceuticals Corp. (“Novartis”). The suit alleges that Novartis, the Company, and other specialty pharmacies violated the federal False Claims Act, as well as the false claims acts of several states, by using |
• | In March 2014, the Company received a subpoena from the United States Attorney’s Office for the District of Rhode Island, requesting documents and information concerning bona fide service fees and rebates received from certain pharmaceutical manufacturers in connection with certain drugs utilized under Part D of the Medicare Program. The Company has been cooperating with the government and collecting documents in response to the subpoena. |
In millions | Pharmacy Services Segment(1)(2) | Retail Pharmacy Segment(2) | Corporate Segment | Intersegment Eliminations(2) | Consolidated Totals | ||||||||||||||
2014: | |||||||||||||||||||
Net revenues | $ | 88,440 | $ | 67,798 | $ | — | $ | (16,871 | ) | $ | 139,367 | ||||||||
Gross profit | 4,771 | 21,277 | — | (681 | ) | 25,367 | |||||||||||||
Operating profit | 3,514 | 6,762 | (796 | ) | (681 | ) | 8,799 | ||||||||||||
Depreciation and amortization | 630 | 1,205 | 96 | — | 1,931 | ||||||||||||||
Total assets | 42,302 | 30,979 | 2,530 | (1,559 | ) | 74,252 | |||||||||||||
Goodwill | 21,234 | 6,908 | — | — | 28,142 | ||||||||||||||
Additions to property and equipment | 308 | 1,745 | 83 | — | 2,136 | ||||||||||||||
2013: | |||||||||||||||||||
Net revenues | $ | 76,208 | $ | 65,618 | $ | — | $ | (15,065 | ) | $ | 126,761 | ||||||||
Gross profit | 4,237 | 20,112 | — | (566 | ) | 23,783 | |||||||||||||
Operating profit | 3,086 | 6,268 | (751 | ) | (566 | ) | 8,037 | ||||||||||||
Depreciation and amortization | 560 | 1,217 | 93 | — | 1,870 | ||||||||||||||
Total assets | 38,343 | 30,191 | 4,420 | (1,428 | ) | 71,526 | |||||||||||||
Goodwill | 19,658 | 6,884 | — | — | 26,542 | ||||||||||||||
Additions to property and equipment | 313 | 1,610 | 61 | — | 1,984 | ||||||||||||||
2012: | |||||||||||||||||||
Net revenues | $ | 73,444 | $ | 63,641 | $ | — | $ | (13,965 | ) | $ | 123,120 | ||||||||
Gross profit | 3,808 | 19,091 | — | (411 | ) | 22,488 | |||||||||||||
Operating profit | 2,679 | 5,636 | (694 | ) | (411 | ) | 7,210 | ||||||||||||
Depreciation and amortization | 517 | 1,153 | 83 | — | 1,753 | ||||||||||||||
Total assets | 36,057 | 29,492 | 1,408 | (736 | ) | 66,221 | |||||||||||||
Goodwill | 19,646 | 6,749 | — | — | 26,395 | ||||||||||||||
Additions to property and equipment | 422 | 1,555 | 53 | — | 2,030 |
(1) | Net revenues of the Pharmacy Services Segment include approximately $8.1 billion, $7.9 billion and $8.4 billion of Retail co-payments for the years ended December 31, 2014, 2013 and 2012, respectively. |
(2) | Intersegment eliminations relate to two types of transactions: (i) Intersegment revenues that occur when Pharmacy Services Segment clients use Retail Pharmacy Segment stores to purchase covered products. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue on a standalone basis and (ii) Intersegment revenues, gross profit and operating profit that occur when Pharmacy Services Segment clients, through the Company’s intersegment activities (such as the Maintenance Choice® program), elect to pick up their maintenance prescriptions at Retail Pharmacy Segment stores instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail Pharmacy segments record the revenue, gross profit and operating profit on a standalone basis. The following amounts are eliminated in consolidation in connection with the item (ii) intersegment activity: net revenues of $4.9 billion, $4.3 billion and $3.4 billion for the years ended December 31, 2014, 2013 and 2012, respectively; and gross profit and operating profit of $681 million, $566 million and $411 million for the years ended December 31, 2014, 2013 and 2012, respectively. |
In millions, except per share amounts | 2014 | 2013 | 2012 | ||||||||
Numerator for earnings per share calculation: | |||||||||||
Income from continuing operations attributable to common stockholders(1) | $ | 4,626 | $ | 4,600 | $ | 3,871 | |||||
Denominator for earnings per share calculation: | |||||||||||
Weighted average shares, basic | 1,161 | 1,217 | 1,271 | ||||||||
Effect of dilutive securities | 8 | 9 | 9 | ||||||||
Weighted average shares, diluted | 1,169 | 1,226 | 1,280 | ||||||||
Earnings per share from continuing operations: | |||||||||||
Basic | $ | 3.98 | $ | 3.78 | $ | 3.05 | |||||
Diluted | $ | 3.96 | $ | 3.75 | $ | 3.02 |
(1) | Comprised of income from continuing operations less amounts allocable to participating securities of $19 million for the year ended December 31, 2014. |
In millions, except per share amounts | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Year | ||||||||||||||
2014: | |||||||||||||||||||
Net revenues | $ | 32,689 | $ | 34,602 | $ | 35,021 | $ | 37,055 | $ | 139,367 | |||||||||
Gross profit | 5,942 | 6,324 | 6,468 | 6,633 | 25,367 | ||||||||||||||
Operating profit | 2,024 | 2,208 | 2,246 | 2,321 | 8,799 | ||||||||||||||
Income from continuing operations | 1,129 | 1,246 | 948 | 1,322 | 4,645 | ||||||||||||||
Loss from discontinued operations, net of tax | — | — | — | (1 | ) | (1 | ) | ||||||||||||
Net income attributable to CVS Health | 1,129 | 1,246 | 948 | 1,321 | 4,644 | ||||||||||||||
Basic earnings per share: | |||||||||||||||||||
Income from continuing operations attributable to CVS Health | $ | 0.96 | $ | 1.07 | $ | 0.82 | $ | 1.15 | $ | 3.98 | |||||||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||
Net income attributable to CVS Health | $ | 0.96 | $ | 1.07 | $ | 0.82 | $ | 1.15 | $ | 3.98 | |||||||||
Diluted earnings per share: | |||||||||||||||||||
Income from continuing operations attributable to CVS Health | $ | 0.95 | $ | 1.06 | $ | 0.81 | $ | 1.14 | $ | 3.96 | |||||||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||
Net income attributable to CVS Health | $ | 0.95 | $ | 1.06 | $ | 0.81 | $ | 1.14 | $ | 3.96 | |||||||||
Dividends per share | $ | 0.275 | $ | 0.275 | $ | 0.275 | $ | 0.275 | $ | 1.10 | |||||||||
Stock price: (New York Stock Exchange) | |||||||||||||||||||
High | $ | 76.36 | $ | 79.43 | $ | 82.57 | $ | 98.62 | $ | 98.62 | |||||||||
Low | $ | 64.95 | $ | 72.37 | $ | 74.69 | $ | 77.40 | $ | 64.95 |
In millions, except per share amounts | First Quarter | Second Quarter | Third Quarter | Fourth Quarter | Year | ||||||||||||||
2013: | |||||||||||||||||||
Net revenues | $ | 30,751 | $ | 31,248 | $ | 31,932 | $ | 32,830 | $ | 126,761 | |||||||||
Gross profit | 5,577 | 5,841 | 6,027 | 6,338 | 23,783 | ||||||||||||||
Operating profit | 1,694 | 1,972 | 2,154 | 2,217 | 8,037 | ||||||||||||||
Income from continuing operations | 954 | 1,125 | 1,255 | 1,266 | 4,600 | ||||||||||||||
Loss from discontinued operations, net of tax | — | (1 | ) | (6 | ) | (1 | ) | (8 | ) | ||||||||||
Net income attributable to CVS Health | 954 | 1,124 | 1,249 | 1,265 | 4,592 | ||||||||||||||
Basic earnings per share: | |||||||||||||||||||
Income from continuing operations attributable to CVS Health | $ | 0.77 | $ | 0.92 | $ | 1.03 | $ | 1.06 | $ | 3.78 | |||||||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | — | $ | — | $ | — | $ | (0.01 | ) | ||||||||
Net income attributable to CVS Health | $ | 0.77 | $ | 0.92 | $ | 1.03 | $ | 1.06 | $ | 3.77 | |||||||||
Diluted earnings per share: | |||||||||||||||||||
Income from continuing operations attributable to CVS Health | $ | 0.77 | $ | 0.91 | $ | 1.02 | $ | 1.05 | $ | 3.75 | |||||||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | — | $ | — | $ | — | $ | (0.01 | ) | ||||||||
Net income attributable to CVS Health | $ | 0.77 | $ | 0.91 | $ | 1.02 | $ | 1.05 | $ | 3.74 | |||||||||
Dividends per share | $ | 0.225 | $ | 0.225 | $ | 0.225 | $ | 0.225 | $ | 0.90 | |||||||||
Stock price: (New York Stock Exchange) | |||||||||||||||||||
High | $ | 56.07 | $ | 60.70 | $ | 62.36 | $ | 71.99 | $ | 71.99 | |||||||||
Low | $ | 49.00 | $ | 53.94 | $ | 56.68 | $ | 56.32 | $ | 49.00 |
In millions, except per share amounts | 2014 | 2013 | 2012 | 2011 | 2010 | ||||||||||||||
Statement of operations data: | |||||||||||||||||||
Net revenues | $ | 139,367 | $ | 126,761 | $ | 123,120 | $ | 107,080 | $ | 95,766 | |||||||||
Gross profit | 25,367 | 23,783 | 22,488 | 20,562 | 20,215 | ||||||||||||||
Operating expenses | 16,568 | 15,746 | 15,278 | 14,231 | 14,082 | ||||||||||||||
Operating profit | 8,799 | 8,037 | 7,210 | 6,331 | 6,133 | ||||||||||||||
Interest expense, net | 600 | 509 | 557 | 584 | 536 | ||||||||||||||
Loss on early extinguishment of debt | 521 | — | 348 | — | — | ||||||||||||||
Income tax provision(1) | 3,033 | 2,928 | 2,436 | 2,258 | 2,178 | ||||||||||||||
Income from continuing operations | 4,645 | 4,600 | 3,869 | 3,489 | 3,419 | ||||||||||||||
Income (loss) from discontinued operations, net of tax | (1 | ) | (8 | ) | (7 | ) | (31 | ) | 2 | ||||||||||
Net income | 4,644 | 4,592 | 3,862 | 3,458 | 3,421 | ||||||||||||||
Net loss attributable to noncontrolling interest | — | — | 2 | 4 | 3 | ||||||||||||||
Net income attributable to CVS Health | $ | 4,644 | $ | 4,592 | $ | 3,864 | $ | 3,462 | $ | 3,424 | |||||||||
Per common share data: | |||||||||||||||||||
Basic earnings per common share: | |||||||||||||||||||
Income from continuing operations attributable to CVS Health | $ | 3.98 | $ | 3.78 | $ | 3.05 | $ | 2.61 | $ | 2.50 | |||||||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | — | ||||||
Net income attributable to CVS Health | $ | 3.98 | $ | 3.77 | $ | 3.04 | $ | 2.59 | $ | 2.50 | |||||||||
Diluted earnings per common share: | |||||||||||||||||||
Income from continuing operations attributable to CVS Health | $ | 3.96 | $ | 3.75 | $ | 3.02 | $ | 2.59 | $ | 2.49 | |||||||||
Loss from discontinued operations attributable to CVS Health | $ | — | $ | (0.01 | ) | $ | (0.01 | ) | $ | (0.02 | ) | $ | — | ||||||
Net income attributable to CVS Health | $ | 3.96 | $ | 3.74 | $ | 3.02 | $ | 2.57 | $ | 2.49 | |||||||||
Cash dividends per common share | $ | 1.10 | $ | 0.90 | $ | 0.65 | $ | 0.50 | $ | 0.35 | |||||||||
Balance sheet and other data: | |||||||||||||||||||
Total assets | $ | 74,252 | $ | 71,526 | $ | 66,221 | $ | 64,852 | $ | 62,457 | |||||||||
Long-term debt | $ | 11,695 | $ | 12,841 | $ | 9,133 | $ | 9,208 | $ | 8,652 | |||||||||
Total shareholders’ equity | $ | 37,963 | $ | 37,938 | $ | 37,653 | $ | 38,014 | $ | 37,662 | |||||||||
Number of stores (at end of year) | 7,866 | 7,702 | 7,508 | 7,388 | 7,248 |
(1) | Income tax provision for the year ended December 31, 2010 includes the effect of the recognition of $47 million of previously unrecognized tax benefits, including interest, relating to the expiration of various statutes of limitation and settlements with tax authorities. |
/s/ Ernst & Young LLP | |
Boston, Massachusetts | |
February 10, 2015 |
(1) | Caremark Rx, L.L.C., the parent of the Registrant’s pharmacy services subsidiaries, is the immediate or indirect parent of several mail order, specialty mail and retail specialty pharmacy subsidiaries, all of which operate in the United States and its territories. |
(2) | CVS Pharmacy, Inc. is the immediate or indirect parent of approximately 45 entities that operate drugstores, all of which drugstores are in the United States and its territories. |
(1) | Registration Statements (Form S-3ASR Nos. 333-187440 and 333-200217) of CVS Health Corporation, and |
(2) | Registration Statements (Form S-8 Nos. 333-49407, 333-34927, 333-28043, 333-91253, 333-63664, 333-139470, 333-141481 and 333-167746) of CVS Health Corporation; |
1. | I have reviewed this annual report on Form 10-K of CVS Health Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors: |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: February 10, 2015 | By: | /S/ LARRY J. MERLO |
Larry J. Merlo President and Chief Executive Officer |
1. | I have reviewed this annual report on Form 10-K of CVS Health Corporation; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors: |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date: February 10, 2015 | By: | /S/ DAVID M. DENTON |
David M. Denton | ||
Executive Vice President and Chief Financial Officer |
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
February 10, 2015 | /S/ LARRY J. MERLO |
Larry J. Merlo | |
President and Chief Executive Officer |
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
February 10, 2015 | /S/ DAVID M. DENTON |
David M. Denton | |
Executive Vice President and Chief Financial Officer |